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Abstract 
Sleep Disturbance in Groups of Patients with Differing Cancer Diagnoses: Testing a Prospective 
Mediation Model of a Symptom Cluster 
Sarah Horsey Simpson, MS 
Jacqueline D. Kloss, Ph.D. 
 
 
 
 Sleep disturbance is one distressing symptom commonly experienced in patients with 
cancer and is associated with negative outcomes (e.g., decreased quality of life, poor treatment 
compliance, and/or physical or psychological symptoms such as pain, fatigue, and depressed 
mood).  Conceptualizing symptoms as clusters is a way to investigate sleep disturbance and its 
relationships to other physical and psychological symptoms commonly experienced in patients 
with cancer.  The purpose of this study was to evaluate the role of sleep disturbance among a 
cluster of symptoms commonly experienced in patients with cancer and examine a prospective 
mediation model whereby sleep disturbance mediates the relationship between pain and 
depressed mood, and then fatigue over time.  Secondary analysis using data collected from a 
pilot study of symptom clusters in patients with cancer undergoing chemotherapy was 
conducted.  Indices of physical and psychological symptoms collected at multiple time points 
during a one month period were available for analyses.  Actigraphy data were collected as an 
objective measurement of sleep disturbance. Results indicated that sleep was poor and previous 
bivariate correlations between sleep disturbance and the other symptoms of interest were 
replicated.  A single factor containing the four symptoms identified was significant via 
Confirmatory Factor Analyses (CFA), supporting the symptom cluster structure recognized.  
Prospective mediation analyses indicated that our proposed model was not significant; however, 
a revised model was supported.  Pain and depressed mood were found to mediate the relationship 
between sleep disturbance and fatigue.  Results confirm that sleep is poor in patients with cancer 
and demonstrate the need to consider or evaluate all four symptoms of the cluster when one or 
more symptoms are identified in clinical or research settings.  The supported mediation model 
provides evidence for an intervention in patients with cancer where sleep disturbance is treated 
by addressing pain and depressed mood, which in turn, reduces fatigue.             
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CHAPTER 1:  INTRODUCTION 
 
The American Cancer Society predicts that approximately 1,638,910 people in the United 
States will be diagnosed with cancer in 2012 (American Cancer Society, 2011).  Due to 
earlier detection and more advanced medical treatment options, many of these people will 
be undergoing treatment and subject to numerous significant physical and mental 
symptoms associated with the actual cancer diagnosis, treatment to eradicate the cancer 
cells, and treatment side effects.  As such, it has become increasingly important to 
address the impact of cancer and its treatment on those diagnosed.  Sleep disturbance is 
one of the most prevalent, debilitating, distressing, and severe symptoms experienced by 
a person with cancer (Ancoli-Israel, 2009; Phillips et al., 2012; Sateia & Lang, 2008; 
Savard, Ivers, Villa, Caplette-Gingras, & Morin, 2011; Savard & Morin, 2001), and is of 
interest to researchers and clinicians alike with the goal of developing more effective 
treatments to reduce symptom burden.  Much of the existing literature in sleep 
disturbance and cancer has focused on insomnia symptoms (difficulty falling asleep, 
difficulty staying asleep, and/or nonrestorative sleep) (DSM-IV-TR; American 
Psychiatric Association, 2000), with two recent studies reporting 36.6% and 59% of 
patients with cancer experiencing insomnia symptoms (Palesh et al., 2010; Savard et al., 
2011).  While a multitude of studies have investigated sleep disturbance, including 
insomnia symptoms, many of these studies fail to adequately define and/or measure 
particular sleep constructs, leading to large variability when describing the prevalence 
and experience of sleep disturbance in the cancer population (Savard & Morin, 2001).  As 
such, the use of standardized measures rather than single item assessments, coupled with 
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objective measurements of sleep variables and appropriate diagnostic classifications are 
now recognized as critical when investigating sleep disturbance in patients with cancer.   
   Research has shown sleep disturbance to have significant psychological and 
physiological consequences, such as reduced quality of life, reduced treatment 
compliance, lack of circadian regulation, alterations in inflammatory biology dynamics, 
and suppressed immune and metabolic functions (Fiorentino & Ancoli-Israel, 2007; 
Irwin, Olmstead, Ganz, & Haque, 2012; Savard & Morin, 2001).  Sleep disturbance is 
also understood to be associated with numerous physical (e.g. pain and fatigue) (Beck, 
Dudley, & Barsevick, 2005) and psychological (i.e. depressive) symptoms (Barsevick, 
Dudley, & Beck, 2006; Cheng & Yeung, 2012).  One way to investigate these complex 
relationships and interactions between sleep disturbance and other common cancer 
symptoms is through symptom clusters (Dodd, Jason, et al., 2001; Miaskowski, 2006; 
Miaskowski et al., 2004; Xiao, 2010). 
 “Symptom clusters” do not currently have a standard “agreed upon” operational 
definition in the literature. However, they can best be described as two to three or more 
symptoms that are related to each other and tend to occur together, but that may or may 
not share a common etiology or shared mechanism (Aktas et al., 2010; Kim, McGuire, 
Tulman, & Barsevick, 2005; Xiao, 2010).  Moreover, symptom cluster research can be 
useful as it is recognized that it is rare for an oncology patient to present with a single 
symptom but instead presents with multiple symptoms; symptom cluster research aims to 
understand how and why symptoms within a cluster are related to one another, in an effort 
to best manage a patient’s symptoms and reduce symptom burden.  To date, much 
remains unknown regarding underlying processes that can explain the clustering of 
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symptoms in a patient with cancer.  What has been investigated in numerous symptom 
cluster studies is which symptoms seem to most commonly cluster together.  Using factor 
analysis techniques, investigators have recognized sleep disturbance, along with fatigue, 
pain, and depressed mood to be among the most commonly experienced symptoms in 
patients with cancer, suggesting their inclusion as a cluster (Bender et al., 2008; Chen & 
Tseng, 2006; Cleeland et al., 2000; Kim & Abraham, 2008).  Further evidence of their 
inclusion in a cluster is the bivariate relationships demonstrated between each of these 
symptoms (Barsevick, Whitmer, Nail, Beck, & Dudley, 2006; Carpenter et al., 2004; 
Coleman et al., 2011; Dodd, Miaskowski, & Paul, 2001; Glover, Dibble, Dodd, & 
Miaskowski, 1995; Kim, Barsevick, & Tulman, 2009; Liu et al., 2012; McMillan, 
Tofthagen, & Morgan, 2008; Miaskowski & Lee, 1999; Spiegel, Sands, & Koopman, 
1994).  For example, sleep disturbance has been found to be positively correlated with 
depression or depressed mood (Ancoli-Israel et al., 2006; Huang & Lin, 2009; McMillan 
et al., 2008), pain (Coleman et al., 2011; Beck, Dudley, & Barsevick, 2005; McMillan et 
al., 2008), and fatigue (Ancoli-Israel et al., 2006; Beck, Dudley, & Barsevick, 2005; 
Coleman et al., 2011; Hoffman, Given, von Eye, Gift, & Given, 2007; Huang & Lin, 
2009; Liu et al., 2012; Miaskowski & Lee, 1999; Wu, Davis, & Natavio, 2012) in 
patients with cancer.  What remains to be understood is how these symptoms in the 
cluster are related to one another.  Specifically, what is the underlying process that 
explains how sleep disturbance, fatigue, pain, and depressed mood cluster together and 
co-occur in a patient with cancer? 
 One potential mechanism by which sleep is related to the other symptoms in the 
cluster is through a mediation model.  To date, only two symptom cluster studies have 
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investigated sleep disturbance in this way.  Beck and colleagues (2005) examined the 
relationships among a cluster of three symptoms, namely pain, sleep disturbance, and 
fatigue in patients with cancer to test whether sleep disturbance mediated the impact of 
pain on fatigue symptoms, finding that pain influenced fatigue directly as well as 
indirectly by its effect on sleep.  This study evidenced that sleep mediated the 
relationships between two other symptoms within the cluster commonly experienced, 
namely fatigue and pain.  However, the researchers acknowledged the limitation of the 
cross sectional nature of the design, making conclusions of temporal relationships not 
possible.  More recently, Huang and Lin (2009) investigated a model by which 
depression mediated the relationship between sleep disturbance and fatigue, but were also 
limited by the cross sectional nature of the design.   
Literature to date clearly indicates that the interrelationships among individual 
symptoms within a symptom cluster are complex and that there may be multiple models 
or mechanisms at work.  Additionally, questions still remain as to how all four individual 
symptoms (i.e. pain, depressed mood, sleep disturbance, and fatigue) are related to one 
another.  One hypothesis is that both pain and depressed mood are related to sleep 
disturbance through fatigue.   
 The purpose of this study was to expand upon previous findings by exploring the 
interrelationships between sleep disturbance and symptoms commonly experienced in a 
patient with cancer.  Additionally, this study allowed for more complete understanding of 
an underlying process that explains how symptoms within a cluster relate.  Our first goal 
was to characterize the nature of sleep as experienced by cancer patients during acute 
treatment using subjective (diary and self-report) and objective (actigraphy) ratings (Aim 
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1).  Our second goal was to expand upon previous findings of positive relationships 
between the symptoms within the cluster (sleep disturbance, fatigue, pain, and depressed 
mood) (Aim 2).  Our third goal was to use confirmatory factor analyses to validate that 
the four symptoms identified from the literature are appropriately included into a single 
symptom cluster (Aim 3).  Our fourth goal was to extend the models proposed by Beck 
and colleagues (2005) and Huang and Lin (2009) as well as to test the extended model in 
a prospective data set to examine the relationships over a cycle of chemotherapy in an 
effort to describe how sleep disturbance, fatigue, pain, and depressed mood are related 
over a cycle of chemotherapy (Aim 4).         
 A review of the literature pertinent to the present study will be provided.  A brief 
background on cancer is presented to highlight the prevalence and severity of this 
disease.  Next, research on cancer and sleep is delineated, with a focus on sleep 
disturbance.  Thereafter, a brief overview of appropriate measurement and diagnostic 
classifications is provided, given the importance of proper measurement tools and use of 
appropriate terminology when conducting research in sleep and cancer.  Subsequently, an 
overview of symptom cluster research is presented, with a focus on the role of sleep 
disturbance in the cluster as well as appropriate statistical methods for evaluating 
symptom clusters.  Following the study’s rationale, methods for the present study are 
provided.  Next, analyses and results of the proposed aims are presented, along with post 
hoc and exploratory analyses.  Finally, a discussion of the results, study limitations, and 
potential areas for future research is offered.  
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CHAPTER 2: LITERATURE REVIEW 
Cancer 
 Cancer is a term used to describe a group of diseases characterized by 
uncontrolled growth of abnormal cells in the body.  A major public health problem in the 
United States and many other parts of the world, cancer affects a large portion of the 
population.  The American Cancer Society estimates that 1 in 2 men and 1 in 3 women 
will likely experience a cancer diagnosis in his or her lifetime (American Cancer Society, 
2011).  While a diagnosis of cancer was once strongly associated with a poor prognosis, 
significant advances in medical treatment options and medical technology have created a 
large population of patients living with cancer.  These patients are experiencing a 
profusion of significant physiological and psychological symptoms as a result of 
experiencing the disease and disease related treatments.  One such symptom in patients 
with cancer is sleep disturbance (Phillips et al., 2012; Savard et al., 2011; Savard & 
Morin, 2001).   
Sleep Disturbance in Cancer 
 Sleep disturbance is well known by clinicians, researchers, and patients to be a 
common problem among the cancer population.  Despite this, it is just within the last 15 
years that researchers have begun to take notice of this neglected problem (Savard & 
Morin, 2001).  Sleep disturbance is a broad term often used to describe the degree to 
which sleep may be disrupted by environmental and personal factors, encompassing any 
and all symptoms of sleep disruption.  The majority of the existing literature in sleep 
disturbance and cancer thus far has focused on insomnia symptoms (Aslan, Sanisoglu, 
Akyol, & Yetkin, 2010; Davidson et al., 2002; Palesh et al., 2010; Sateia & Lang, 2008; 
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Savard et al., 2011; Savard & Morin, 2001).  Insomnia is a particular type of sleep 
disturbance characterized by difficulty falling asleep, difficulty staying asleep, and/or 
nonrestorative sleep, resulting in daytime dysfunction (American Psychiatric Association, 
2000).  
 Prevalence. Comorbid insomnia or insomnia symptoms have been found to affect 
between 30% to 75% of newly diagnosed or recently treated cancer patients (Davidson et 
al., 2002; Palesh et al., 2010; Sateia & Lang, 2008; Savard et al., 2011; Savard & Morin, 
2001).  As a comparison, approximately 33% of the general population reports some 
insomnia symptoms and 16-21% meets criteria for primary insomnia (Ohayon, 2002).  
The National Heart, Blood, and Lung Institute more recently estimated that 
approximately 64 million Americans suffer from insomnia each year, making insomnia 
the most common sleep disorder in the general population (National Heart, Lung, and 
Blood Institute, 2007).  Specific insomnia symptom complaints in a patient with cancer 
include difficulty falling asleep and difficulty staying asleep, coupled with frequent and 
prolonged nighttime awakenings.  Daytime impairment occurs as a result of these sleep 
difficulties.  Comorbid Insomnia Disorder (i.e. insomnia disorder comorbid with cancer) 
is characterized by one or more of these complaints but also meets standard diagnostic 
criteria that include frequency and duration specifiers (DSM-IV-TR; (American 
Psychiatric Association2000; Savard & Morin, 2001).   
 Three large empirical investigations were specifically designed to investigate the 
prevalence of comorbid insomnia disorder or insomnia symptoms in oncology patients.  
First, Davidson et al., (2002) offered a brief sleep survey that inquired about the presence 
or absence of various sleep phenomena over the previous four weeks to all breast, 
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gastrointestinal, genitourinary, gynecologic, or lung cancer patients attending clinic at a 
regional cancer center.  During a three month period, 982 cancer patients in all stages of 
disease and treatment completed the questionnaire.  Comorbid insomnia was 
appropriately defined by the answer of “yes” to questions asking about a) trouble 
sleeping in the past 4 weeks; b) the trouble occurred on at least 7 of the previous 28 
nights; and c) the trouble interfered with daytime functioning.  These questions were 
designed by the researchers to assess insomnia using a standard diagnostic classification 
system (American Psychiatric Association, 2000; Savard & Morin, 2001).  Patients also 
specified the type of sleep trouble (i.e. trouble falling asleep, waking up too early, etc.).  
Comorbid insomnia was reported by 300 patients (30.5%) with waking several times 
during the night most common (76%), followed by trouble falling asleep (44%), waking 
for a long time (35%), and waking too early (33%).  Over half of patients reported having 
some combination of these problems and the median duration of insomnia reported was 
18.9 months.  Insomnia onset was reported to be within the period 6 months pre-
diagnosis to 18 months post diagnosis in 48.2% of patients, and of interest, a large 
number of patients indicated that their insomnia onset corresponded exactly with the date 
of disease diagnosis.   
 More recently, Palesh et al. (2010) surveyed 823 oncology patients with any 
diagnosis of cancer from 18 private practice oncology groups around the United States 
that were part of the National Cancer Institute Community Clinical Oncology Program.  
Patients were in active chemotherapy treatment and completed questionnaires on Day 7 
of cycles 1 and 2.  Insomnia syndrome was measured via 6 questions of the Hamilton 
Depression Inventory that assessed frequency, duration, and severity of sleep problems in 
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the previous 2 weeks.  Researchers were unable to measure the impact of insomnia 
symptoms on daytime functioning, thus the term “insomnia syndrome” was used instead 
of comorbid insomnia.  The researchers used a data reduction approach to classify 
patients into three groups: 1) insomnia syndrome patients reported  difficulty falling 
asleep, difficulty staying asleep, and/or early morning awakenings for at least 3 days a 
week for 2 weeks, with each episode lasting at least 30 minutes; 2) patients coded as 
having insomnia symptoms reported some sleep disturbance but did not meet criteria for 
frequency or duration; and 3) good sleepers reported no sleep difficulties on any of the 6 
items.  During cycle 1, 36.6% of patients reported insomnia symptoms and 43% met 
criteria for insomnia syndrome.  During cycle 2, 33.1% of patients continued to report 
insomnia symptoms while 35.2% of patients met criteria for insomnia syndrome.  As 
expected, a significant positive correlation was found between insomnia at cycle 1 and 
cycle 2, with an average of 60% of patients reporting their sleep complaints unchanged.  
Interestingly, 10% of good sleepers at cycle 1 developed insomnia syndrome at cycle 2 
and an additional 24.6% developed insomnia symptoms.  Looking across disease sites, 
patients with lung and breast cancer had the highest prevalence of insomnia syndrome, 
which is consistent with prior research (Davidson et al., 2002; Silberfarb, Hauri, Oxman, 
& Schnurr, 1993).  Also of note, there were no significant gender differences in insomnia 
complaints, despite a higher prevalence of insomnia disorder in women than men in the 
general population (Ohayon, 2002).   
Most recently, Savard et al. (2011) followed 962 oncology patients with a first 
diagnosis of nonmetastatic cancer and scheduled to receive curative surgery.  Participants 
completed an insomnia diagnostic interview at the preoperative stage, as well as 2, 6, 10, 
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14, and 18 months post surgery.  Similar to Palesh et al. (2010), the researchers used 
DSM criteria to categorize participants into good sleepers, patients with insomnia 
symptoms, and patients with insomnia syndrome.  At baseline, rates were consistent with 
prior research with 43% of participants meeting criteria for insomnia syndrome and 36% 
with insomnia symptoms.  At cycle 2, rates slightly decreased, with 35% of participants 
meeting criteria for insomnia syndrome and 33% with insomnia symptoms.  It should be 
recognized that these rates still remain higher than those seen in the general population.   
   Aside from these three large studies, sleep disturbance and insomnia symptoms 
have been investigated and confirmed in specific cancer disease populations, during 
specific disease stages, and at many different stages throughout the treatment trajectory 
(see Savard & Morin, 2001 for a review).  To summarize, while insomnia symptom rates 
do vary somewhat due to the heterogeneous nature of the data, all studies have clearly 
indicated that insomnia symptoms are prevalent in all disease populations, during all 
cancer stages, and can occur prior to treatment, at any point during treatment, and/or well 
after treatment. 
 Classification and Evaluation. It should be noted that effective identification 
and assessment of sleep disturbance in a cancer population requires a fundamental 
working knowledge of diagnostic classification.  As can be seen above, insomnia and 
insomnia symptoms are the sleep disturbances of greatest interest in the literature 
examining sleep in cancer patients.  However, the literature currently lacks  consensus or 
systematic use of appropriate diagnostic classification systems or terminology across  
studies when defining or measuring constructs, which contributes great variability across 
studies on how sleep disturbance is defined and measured (Barsevick, Dudley, & Beck, 
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2006; Miaskowski et al., 2004; Savard & Morin, 2001).  As pointed out by Savard and 
Morin (2001), many studies lack an operational definition of insomnia and/or variable 
assessment methods necessary to evaluate its presence and clinical significance.  In light 
of these difficulties in diagnostic classification and assessment, researchers investigating 
sleep in cancer are beginning to recognize that accurate assessment of sleep disturbance 
(including insomnia symptoms and comorbid insomnia disorder) in cancer patients 
requires a more thorough evaluation than can be provided by a single item response used 
in many earlier studies (Lee & Ward, 2005).  Specifically, the use of standardized 
assessments specifically designed to evaluate sleep quality and disturbance such as the 
Pittsburgh Sleep Quality Index (PSQI) or the Insomnia Severity Index (ISI), are needed 
(Bastien, Valliares, & Morin, 2001; Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). 
 Another important issue when measuring and evaluating sleep disturbance in this 
population is whether data are subjective versus objective in nature and the implications 
of each tool.  The majority of researchers to date have used subjective assessment 
methods that inquire about sleep difficulties and gather self report information from the 
patient via questionnaires and/or interviewing techniques (as seen in the three large 
prevalence studies described above).  While these techniques are relatively easy to use 
and can provide a wealth of useful information, this information may be biased due to the 
accuracy of self-reported symptoms.  Another assessment option is to use more objective 
measures of sleep disturbance, often in combination with subjective measurements.   
 The two objective methodologies typically used when examining sleep are: wrist 
actigraphy, which measures sleep/wake activity patterns and circadian rhythms over 
multiple days (Ancoli-Israel et al., 2003; Brown, Smolensky, D'Alonzo, & Redman, 
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1990); and polysomnography, which is considered the gold standard for measuring sleep 
stages and sleep disturbances for one night.  Due to high cost and the time consuming 
nature of these methods, few studies have utilized objective measures to examine sleep in 
cancer patients.  What little has been done suggests that objective measurements of sleep 
can provide different information about a person’s sleep compared to subjective measures 
of the same construct, thus highlighting a need to gather both subjective and objective 
measurements of sleep when possible to have the most complete picture.  For example, 
Silberfarb et al. (1993) used polysomography (PSG) to investigate sleep patterns in 32 
breast and lung cancer patients of various disease stages averaging approximately 7-11 
months after their diagnosis.  Diagnostic interviews, visual analog scales, and self report 
sleep logs were also used to gather subjective reports of sleep.  The researchers found that 
lung cancer patients appear to sleep poorly when objectively studied by the 
polysomnographic measurements of a sleep laboratory, but breast cancer patients slept 
well according to objective polysomnographic tracings.  In contrast, the sleep logs 
completed by lung cancer patients, the semistructured interview completed by the 
investigators, and the patient-completed visual analog scales all indicated that lung cancer 
patients underreported disturbances in sleep whereas breast cancer patients reported more 
difficulty.  These findings are important in that they provide one of the first objective 
measurements of sleep in cancer patients, but they also indicate that subjective reports of 
sleep may not match objective sleep findings in this population.  Specifically, patients 
may under- or over- report sleep disturbance on subjective measures.    
Polysomography has also been used to investigate sleep characteristics as well as 
changes in sleep before and after the completion of chemotherapy (Roscoe et al., 2011).  
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Twenty six patients with breast, colorectal, or lymphoma underwent PSG at three time 
points: prior to their first chemotherapy treatment, approximately 3 weeks following last 
chemotherapy treatment, and approximately 12 weeks following last chemotherapy 
treatment.  Results indicated that while sleep characteristics remain relatively stable 
during the stress of cancer and its treatment, sleep was disturbed with patients sleeping 
less than 7 hours per night at all three time points.  No information regarding patient 
perceptions of their sleep was provided.   
 Actigraphy, another objective measurement tool, is described as an approximate 
measure of sleep, with about 90% accuracy compared with polysomnography (Cole, 
Kripke, Gruen, Mullaney, & Gillin, 1992).  Actigraphy is a wrist watch sized device 
typically worn on the non-dominant hand that measures and records movement across 
multiple space planes.  This movement is converted into electrical signals that are stored 
in the device’s memory as a counts/minutes index and can be downloaded and interpreted 
to describe patterns of movement in 24 hour cycles.  A marker on the side of the device is 
pressed when the wearer rises from bed for the day and gets into bed for the night, along 
with any time the device is taken off (e.g., to bathe).  Using specific time period 
guidelines and/or referencing concurrent self report sleep diaries, researchers can 
accurately estimate periods of inactivity as sleep and periods of movement as 
wakefulness (Brown et al., 1990).  Portable and less time intensive than PSG, actigraphy 
has been used by several researchers to describe sleep patterns in a cancer population 
(Ancoli-Israel et al., 2003; Miaskowski & Lee, 1999; Wang, Chang, & Lin, 2010).  
Findings have shown cancer patients to experience significant sleep disturbance, 
including a long sleep onset latency, fragmented sleep, and low sleep efficiency (SE; a 
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percentage defined as the amount of sleep given the amount of time in bed) (Berger, 
1998; Berger & Farr, 1999; Mormont, De Prins, & Lavi, 1996; Mormont & Waterhouse, 
2002; Roscoe et al., 2002).  These sleep disturbances have been found prior to the start of 
chemotherapy (Ancoli-Israel et al., 2006; Berger, Farr, Kuhn, Fischer, & Agrawal, 2007), 
during chemotherapy (Berger, 1998; Kuo, Chiu, Liao, & Hwang, 2006; Liu et al., 2012), 
as well as after chemotherapy is completed (Berger et al., 2003). 
 Similar to PSG, actigraphy data has been found to differ from subjective sleep 
diary data.  For example, in a nonclinical population, Total sleep time (TST) as reported 
by sleep logs was over-estimated by an average of 48 minutes when compared to 
actigraphy collected over a 1 week period (Lauderdale, Knutson, Yan, Liu, & Rathouz, 
2008).  Also, in a sample of patients with non-small cell lung cancer, Wang, Chang, and 
Lin (2010) compared 1 week of actigraphy and sleep logs to determine congruence and 
while results indicated an overall high congruence (87%) as measured by Pearson 
correlation coefficients, Sleep onset latency (SOL) was slightly under-estimated and TST 
and SE were slightly over-estimated by sleep log compared to actigraphy.  Wake after 
sleep onset (WASO) was not collected via sleep logs and could not be compared to 
actigraphy data.   
 To summarize, one difficulty in synthesizing sleep disturbance in cancer research 
has been the inconsistent use of diagnostic classification systems.  Using appropriate 
diagnostic definitions with both subjective and objective methods is a useful option to 
obtain more complete and accurate information regarding sleep characteristics.  This 
systematic use of appropriate diagnostic classification systems and multiple measurement 
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methodologies across studies will allow for more easily interpreted findings that can be 
appropriately compared to one another.   
Symptom Clusters 
 Sleep disturbance is clearly a symptom commonly experienced in a cancer 
population, and with it patients often experience a range of significant psychological and 
physiological consequences that can impact survival, quality of life, and distress 
(Kirkova, Walsh, Aktas, & Davis, 2010; Phillips et al., 2012; Sharma et al., 2011).  As 
such, this critical role of sleep in disease has been explored via complex interactions 
between sleep disturbance and other common cancer symptoms, most notably fatigue, 
depressed mood, and pain (Barsevick, 2007; Brant et al., 2011; Cheng & Yeung, 2012; 
Coleman et al., 2011; Miaskowski, Aouizerat, Dodd, & Cooper, 2007).  Symptom 
clusters are a new way to investigate and understand this role of sleep disturbance in a 
cancer population while taking into account symptom interactions and interrelationships.   
 The symptom experience in an individual with cancer is both complex and 
dynamic.  It is rare for an oncology patient to present with a single symptom and research 
has shown that the majority of oncology patients present with multiple symptoms that can 
be attributed to their disease and/or treatments (Portenoy et al., 1994).  Symptoms 
 can occur at diagnosis, during or after the treatment experience, and/or may have 
manifested prior to the cancer diagnosis but remain or are exacerbated by the disease or 
disease related treatments.  Additionally, symptoms may interact with one another in 
ways that are currently poorly understood.  In an effort to understand these complex 
relationships and create appropriate treatments for symptoms commonly experienced, 
research examining symptom prevalence, assessment, and management in oncology 
25 
 
 
patients has recently shifted its focus from a single symptom such as sleep disturbance to 
multiple symptoms experienced concurrently in a cancer population (Barsevick, 2007; 
Dodd et al., 2001; Kirkova, Aktas, Walsh, & Davis, 2011; Miaskowski, 2006; 
Miaskowski et al., 2004; Xiao, 2010).  These manifestations of multiple symptoms, 
named symptom clusters, have been described as the “new frontier” in symptom 
management research (Aktas et al., 2010; Barsevick, 2007; Miaskowski et al., 2004; 
Xiao, 2010), with a significant amount of research focused on understanding this 
construct in the past thirteen years.   
 In 2001, Dodd et al. first defined a symptom cluster as three or more concurrent 
symptoms that are related to each other but are not required to share the same mechanism 
or etiology.  Kim et al. (2005) later redefined a symptom cluster as two or more 
symptoms that are related to each other and that occur together but may or may not share 
a common etiology.  The researchers also extended the definition by stating that symptom 
clusters are composed of stable groups of symptoms and are relatively independent of 
other clusters, which may indicate specific underlying dimensions or shared mechanism.  
To our knowledge, no clarification or determination of the critical elements that need to 
be met to establish a symptom cluster (e.g. 2 or 3 symptoms needed to be called a cluster) 
exists.  Thus, consensus leading to the adoption of a standard definition is needed for all 
research endeavors.  What is agreed upon is a need to explore the many unanswered 
questions with regard to how symptoms within a cluster are related and how they 
influence a cancer patient’s outcome.   
 Sleep disturbance is prevalent in cancer patients, so it is not surprising that sleep 
disturbance is commonly investigated as one symptom within a cluster (Kirkova et al., 
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2011; Xiao, 2010).  In addition to sleep symptoms, other symptoms most commonly 
investigated in symptom cluster research include fatigue, depressed mood, and pain 
(Barsevick, Dudley, et al., 2006; Berger & Higginbotham, 2000; Byar, Berger, Bakken, 
& Cetak, 2006; Carpenter et al., 2004; Cheng & Yeung, 2012; Coleman et al., 2011; 
Dodd et al., 2001; Given, Given, Azzouz, Kozachik, & Stommel, 2001; Liu et al., 2009; 
Oh, Seo, Jeong, & Seo, 2012; So et al., 2009).  Because most people with cancer suffer 
from multiple symptoms, these most common and severe four symptoms will be the 
focus of this literature review.  
Statistical Approaches to Investigate Symptom Clusters 
 One way to investigate symptom clusters is to use bivariate correlational models 
to investigate relationships among symptoms.  These models allow researchers to 
examine shared variance among symptoms.  Many studies have used this approach to 
document positive correlations between sleep disturbance, fatigue, depression, and pain 
in patients with cancer.  Specifically, sleep disturbance has been found to be positively 
correlated with depression or depressed mood (Ancoli-Israel et al., 2006; Huang & Lin, 
2009; McMillan et al., 2008; Mystakidou et al., 2007), pain (Coleman et al., 2011; Beck, 
Dudley, & Barsevick, 2005; McMillan et al., 2008; Mystakidou et al., 2007; Sharma et 
al., 2011), and fatigue (Ancoli-Israel et al., 2006; Beck, Dudley, & Barsevick, 2005; 
Coleman et al., 2011; Hoffman et al., 2007; Huang & Lin, 2009; Liu et al., 2012; Wu, 
Davis, & Natavio, 2012) in patients with cancer.  Results are mixed regarding the 
relationship between depression or depressed mood and fatigue, with Carpenter et al. 
(2004) finding no relationship while other studies demonstrating moderate to strong 
correlations between depression or depressed mood and fatigue (Huang & Lin, 2009; 
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Kim et al., 2009).  A weak to strong correlations between fatigue and pain has also been 
documented (Beck, Dudley, & Barsevick, 2006; Carpenter et al., 2004;  Dodd et al., 
2001; Gaston-Johannsson et al., 1999; Kim et al., 2009; Mystakidou et al., 2007).  
Finally, depression or depressed mood and pain have been found to be positively 
correlated (McMillan et al., 2008; Mystakidou et al., 2007; Spiegel et al., 1994).  These 
bivariate relationships provide confirming support that these symptoms appear to be 
related to one another, a necessary factor when identifying a symptom cluster.  However, 
these correlational models alone are not adequate to describe the nature of the 
relationships among the symptoms or provide an understanding of what types of 
processes may lead to the clustering of symptoms.   
Factor analysis is another approach that has been used by researchers to move 
beyond the bivariate relationships and attempt to examine the complexity of these 
relationships (Skerman, Yates, & Battistutta, 2009).  Factor analysis can be used to 
examine shared variance among groups of symptoms by revealing underlying structure or 
pattern in data.  This approach can be used to discover a group or subset of variables 
(identified as factors but can also be called clusters within this manuscript) that are 
correlated to one another but independent of other groups.  Factors may reflect 
underlying processes responsible for the correlations among symptoms (Tabachnick & 
Fidell, 2001), making factor analysis a useful tool to identify a symptom cluster that 
could then be used to test for a hypothesized mechanism or process that accounts for the 
clustering.  Factor analysis methods include exploratory factor analysis (EFA) and 
confirmatory factor analysis (CFA).  The goal of EFA is to identify a coherent set of 
interrelated variables (e.g. sleep disturbance, pain, depressed mood, fatigue) that are 
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indicators of one or more underlying factors (e.g. cancer related symptom factor).  In 
contrast, CFA is used to statistically test (validate) the hypotheses of the relationships 
among symptoms as recognized from the literature.  It should be acknowledged that other 
analysis approaches can also be used to examine structure in data (i.e. cluster analysis, 
principal component analysis, structural equation modeling) (Kim et al., 2005; Kirkova et 
al., 2011).  However, these tools are beyond the scope of this manuscript and will not be 
discussed.     
Given the differences in study samples of patients with cancer, and wide range of 
assessment tools used to measure symptoms in studies, it is not surprising that different 
factors or symptom clusters have been identified via EFA.  To briefly summarize the 
research to date that has included sleep disturbance as a symptom, each have described 
slightly different symptom clusters but share many of the same symptoms.  One to three 
symptom clusters have been determined in these studies and each cluster has ranged from 
two to eleven separate symptoms (Bender et al., 2008; Chen & Tseng, 2006; Cleeland et 
al., 2000; Kim, Barsevick, Tulman, & McDermott, 2008; Okuyama et al., 2003; Wang et 
al., 2008; Wang et al., 2006).  Comparing the findings and focusing on our symptoms of 
interest, fatigue, sleep disturbance, pain, and emotional distress or sadness appear 
together in one or more clusters often, providing additional support of their 
interrelationships.  Interestingly, to our knowledge, CFA has never been used to 
investigate a single factor consisting of these four variables, despite significant evidence 
that suggests these particular symptoms are highly interrelated (Beck et al., 2005; 
Carpenter et al., 2004; Coleman et al., 2011; Hoffman et al., 2007; Irwin et al., 2012; 
McMillan et al., 2008; Miaskowski & Lee, 1999; Sharma et al., 2011; Wang et al.2008).  
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Furthermore, these approaches alone are unable to determine the nature of relationships 
among symptoms.   
Another approach to investigating symptom clusters is to use more complex path 
analysis models, specifically mediation models (Baron & Kenny, 1986), in which one 
symptom is proposed to influence another symptom through its relationship to a third 
symptom.  In other words, the “mediator” variable accounts for the relationship between 
two other variables, the independent and dependent variables, also called predictor and 
criterion variables.  Mediators speak to how or why certain symptom are related, moving 
beyond correlations between variables and providing a mechanistic explanation as to how 
symptoms within a cluster are related and why certain symptoms tend to “cluster” 
together.   
Three conditions are necessary to establish classic mediation as described by 
Baron and Kenny (1986) (see Figure 1).  First, variations in levels of the independent 
variable must significantly account for variations in the dependent variable (path c).  
Second, variations in levels of the independent variable must significantly account for 
variations in the presumed mediator (path a).  Third, variations in the mediator must 
significantly account for variations in the dependent variable (path b).  When these 
preconditions are met, a mediating effect (also known as the indirect effect) can be tested.  
When paths a and b are controlled, a previously significant relation between the 
independent and dependent variables is no longer significant (path c), also known as the 
direct effect.  The strongest demonstration of mediation occurs when this path is zero but 
partial mediation can occur when the previously significant relationship between the 
independent and dependent variables is reduced but not eliminated.   
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MacKinnon, Fairchild, and Fritz (2007) recently demonstrated error with the first 
condition of an overall significant relationship between the independent and dependent 
variables (path c) in order for mediation to exist, pointing out several scenarios where 
significant mediation exists but the overall effect of the independent variable on the 
dependent variable is not significant.  For example, in inconsistent mediation, the 
mediation effect is opposite in sign to the direct effect.  In this model, the independent 
variable and mediator are negatively correlated yet the mediator and dependent variable 
are positively correlated.  As a result, the direct effect will be very small because the 
indirect and direct effects cancel one another out.  However, mediation does occur.  The 
researchers conclude that significance between the independent variable and dependent 
variable should not be considered a required condition for mediation to occur.  As a 
result, researchers have begun to focus more exclusively on the relationships between the 
independent variable and the mediator as well as the mediator and the dependent variable.      
While Baron and Kenny (1986) mediation model is most frequently used in 
applied science research, other tools to examine mediation models exist and may be more 
appropriate.  As noted in MacKinnon and colleagues' simulation study of indirect effects 
(MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002), when compared to several 
other mediation approaches, the Baron and Kenny approach was found to have very low 
power, unless the effect or sample size is large.  The joint significance test of  and  is 
an alternative approach has been found to have power of at least .80 with a medium effect 
size and a sample size of 100 (MacKinnon et al., 2002).  This method tests 1) whether the 
independent variable is related to the mediator by predicting the mediator from the 
independent variable in a regression analysis (path a), and 2) whether the mediator is 
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related to the dependent variable by predicting the dependent variable from the mediator 
in a regression analysis that also includes the independent variable as a predictor (path b; 
see Figure 1).  If the two paths are jointly significant, meaning that both a and b paths are 
significant, mediation exists.  Of interest, this test does not require a test of significance 
between the independent and dependent variables.  In a recent review article aimed at 
investigators in applied science settings, Krause et al. (2010) critique various mediation 
analyses and concluded that the joint significance test of  and  yields the most power 
and the most accurate type I error rates when compared to other tests of mediation, while 
being easily computed and versatile.   
While the joint significance test of  and provides information regarding the 
presence or absence of a mediation effect, the Sobel test (Sobel, 1982, 1986) provides a 
formal significance test of the indirect effect, thereby quantifying the indirect effect 
rather than simply inferring its existence from a set of tests on its constitute paths.  This 
test divides the product of the path coefficients of a and b by the product the standard 
error of the path coefficients to yield a critical value that can be compared with a critical 
value from the standard normal distribution.   In other words, the ratio of ab to its 
standard error is used to test the null hypothesis that the true indirect effect is zero, with a 
p value derived from standard normal distribution.  The Sobel test is widely used and 
accepted when examining mediation models due to its intuitive appeal and power 
(MacKinnon et al., 2002).           
These mediation models have been used to investigate symptom clusters in four 
known studies to date, with two investigating sleep disturbance.  Beck, Dudley, and 
Barsevick (2005) examined the relationships among a cluster of three symptoms, namely 
32 
 
 
pain, sleep disturbance, and fatigue in 84 patients with all types of cancer currently 
undergoing treatment, with an interest in understanding the extent to which pain intensity 
affected sleep disturbance and fatigue, as well as to test whether sleep disturbance 
mediated the impact of pain on fatigue symptoms.  The researchers found that sleep 
disturbance did partially mediate the relationship between pain and fatigue. They 
cautiously suggested that strategies to improve sleep via better pain management may 
contribute to decreased fatigue.   This study provides evidence of sleep mediating the 
relationships between two other symptoms within the cluster commonly experienced, 
namely fatigue and pain.  However, one limitation acknowledged by the researchers was 
the cross sectional nature of the design, making conclusions of temporal relationships not 
possible.  Additionally, questions still remain as to how another symptom commonly 
occurring in the cluster of symptoms and correlated with each of the individual symptoms 
(i.e. depressed mood) is related.   
 Huang and Lin (2009) also used a mediation model in their exploration of the 
relationship between depression, fatigue, and sleep disturbance in a homogenous sample 
of Taiwanese patients with hepatocellular carcinoma who were scheduled to receive 
transcatheter arterial embolization.  Results supported their hypothesis that depression 
mediates the effect of sleep disturbance on fatigue.  Pointing to studies that show 
insomnia preceding the onset of depression and commonalities in the symptoms of 
fatigue and depression, the researchers concluded that sleep disturbance, specifically 
insomnia, may actually trigger depression, which in turn leads to fatigue.  However, like 
Beck, Dudley, and Barsevick (2005), this study was also cross sectional in nature, thus 
lacking the ability to appropriately make conclusions regarding temporal relationships.  
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Additionally, the researchers did not acknowledge or explore the bidirectional nature of 
these relationships, namely that sleep disturbance may also act as a mediator between 
depressed mood and fatigue.  The relationships between symptoms are complex, and it is 
not surprising that studies have found both insomnia to be a predictor of depression 
(Perlis et al., 2006) as well as depression to be a predictor of insomnia (Palesh et al., 
2007).  Finally, pain was not measured or addressed, despite significant evidence in the 
literature via factor analysis that pain groups together with depressed mood, sleep 
disturbance, and fatigue.   
While no study to date has used a mediation model to investigate the four 
symptoms of interest, the results of these two mediation model studies suggest that 
multiple complex relationships among the symptoms may exist and mediation is one 
useful way to explore how symptoms within a cluster are interrelated.  One potential 
model that has yet to be investigated is that both pain and depressed mood first account 
for the variance in sleep disturbance, which then in turn, accounts for the variance in 
fatigue.  To properly consider this proposed model, a more in-depth exploration of the 
literature describing known temporal relationships among these symptoms is warranted.   
Temporal Relationships among Symptoms 
 While few in numbers, longitudinal or prospective designs investigating the 
relationships of interest do demonstrate temporal sequence among some symptoms in a 
cancer population.  For example, sleep disturbance predicts increased levels of fatigue in 
the literature.  Miaskowski and Lee (1999) examined fatigue and sleep disturbance in 
patients being treated with radiation therapy for bone metastases and found that 
improvements in fatigue from evening to morning was associated with higher total sleep 
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time, decreased nighttime awakenings, and a better sleep efficiency, suggesting that sleep 
disturbance may predict increased fatigue over time.  Another study found that women in 
chemotherapy who engaged in more napping behavior and experienced more nighttime 
awakenings had higher levels of fatigue over time (Berger & Farr, 1999).  Both of these 
studies provide support that sleep disturbance may predict fatigue in patients with cancer.   
In contrast, both pain and depression have been found to predict sleep disturbance 
(Palesh et al., 2007).  In a sample of 93 women with metastatic breast cancer, more 
severe pain at baseline predicted more difficulties in initiating sleep at a later date 
compared to those with less severe pain.  Similarly, more severe depression at baseline 
predicted more nighttime awakenings and daytime sleepiness at subsequent time points 
compared to those with less severe depression.  However, this depression-sleep 
disturbance relationship may be bidirectional, as insomnia has also been found to predict 
depression in community samples (Ford & Kamerow, 1989; Perlis et al., 2006).  To our 
knowledge, no study to date has examined sleep disturbance or insomnia as a predictor of 
depressed mood or depression in a sample of patients with cancer.   
 A similar bidirectional relationship appears in the literature describing the 
relationship between pain and depressed mood, which often coexist in cancer patients 
(McMillan et al., 2008; Mystakidou et al., 2007; Spiegel et al., 1994).  As before, the 
exact nature of this relationship in patients with cancer is unknown, as all the available 
data are cross-sectional and therefore do not clarify the causal relationship between the 
two variables.  Extending the search into literature examining other patient populations 
provides little clarity.  One study investigating temporal relationships between pain and 
depression using a sample with chronic musculoskeletal pain concluded that both that 
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depression promotes pain and pain promotes depression, suggesting that the relationship 
between these symptoms may be bidirectional (Magni, Moreschi, Rigatti-Luchini, & 
Merskey, 1994).  Similarly, a paper reviewing a series of epidemiological studies that 
examined the pain-depression relationship in population-based or primary care samples 
concluded that pain and depression are frequently comorbid and hypothesized that pain 
may be a somatic expression of unacknowledged depression and/or depression may a 
consequence of chronic pain (Von Korff & Simon, 1996).   
In summary, these investigations provide some guidance regarding the temporal 
relationships among the symptoms of interest but also validate the need for a model 
informed by the literature that can better explain how all four of the symptoms commonly 
experienced by a person with cancer (pain, depressed mood, sleep disturbance, fatigue) 
might relate to one another.  One potential model is that both depressed mood and pain 
(which are highly comorbid) account for the variance in sleep disturbance, which then 
accounts for the variance in fatigue in patients with cancer.  In other words, sleep 
disturbance acts as a mediator of the relationship between comorbidly occurring pain + 
depressed mood and fatigue.      
Proposed Study 
From the literature we know that cancer patients experience significant 
physiological and psychological symptoms, which tend to cluster together.  Sleep 
disturbance is consistently found to be one of the most prevalent, distressing, and severe 
symptoms experienced by a person with cancer.  As sleep disturbance is often 
experienced in combination with other symptoms (e.g. pain, depressed mood, fatigue), 
one way to study sleep disturbance is through symptom clusters.  Symptoms within a 
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cluster are known to have complex interrelationships and one way to understand these 
relationships is through the investigation of underlying processes that explain how 
symptoms within a cluster are related to one another.  The role of sleep disturbance 
within the cluster may be explained through one such underlying process.  Specifically, 
perhaps sleep disturbance acts as a mediator in the relationship between depressed mood 
+ pain and fatigue.  In other words, pain and depressed mood work together to account 
for variance in sleep disturbance, which then accounts for variance in fatigue (see Figure 
2).     
This model extends previous work by Beck, Dudley and Barsevick (2005) who 
proposed sleep disturbance to be a mediator between pain and fatigue but did not include 
depressed mood or depression within the model.  The proposed model also extends the 
work by Huang and Lin (2009) by considering the bidirectional nature of the relationship 
between depressed mood and sleep disturbance as well as including pain as a symptom of 
interest.  Finally, examining this model in a prospective design allows for the most 
appropriate use of a mediation model (Holland, 1986; Mackinnon & Fairchild, 2009) and 
provides a better understanding of how the symptoms are experienced together over time.        
It seems reasonable that poor sleep could explain the relationship between pain + 
depressed mood and fatigue.  Studies have demonstrated correlations between pain and 
sleep disturbance (Coleman et al., 2011; Beck, Dudley, & Barsevick, 2005; McMillan et 
al., 2008; Mystakidou et al., 2007; Sharma et al., 2011), as well as depressed mood and 
sleep disturbance (Ancoli-Israel et al., 2006; Huang & Lin, 2009; McMillan et al., 2008; 
Mystakidou et al., 2007), which is expected in a mediation model.  Sleep is a restorative 
process and some researchers have theorized that pain can cause sleep fragmentation and 
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give rise to reports of unrefreshing sleep (Lavigne, McMillan, & Zucconi, 2005).  
Depression has also predicted sleep disturbance over time in patients with cancer (Palesh 
et al., 2007).  While temporal relationships are unclear, pain and depressed mood are 
commonly comorbid in patients with cancer (Magni et al., 1994; Von Korff & Simon, 
1996) and with several studies have recognized pain and depressed mood to be positively 
correlated (McMillan et al., 2008; Spiegel et al., 1994).  Considering the relationship 
between sleep disturbance and fatigue, many studies have demonstrated strong 
correlations between the two symptoms (Beck et al., 2005; Hoffman et al., 2007; Liu et 
al., 2012; Miaskowski & Lee, 1999; Wu et al., 2012) and sleep disturbance has even been 
found to predict fatigue in two prospective studies (Berger & Farr, 1999; Miaskowski & 
Lee, 1999).  Interestingly, the relationships between depressed mood and fatigue as well 
as pain and fatigue are less understood.  Results regarding correlations between 
depression or depressed mood and fatigue are inconsistent, with Carpenter et al. (2004) 
finding no relationship while other studies have found moderate to strong correlations 
between depression and fatigue (Huang & Lin, 2009; Kim et al., 2009). Furthermore, the 
correlations between pain and fatigue that have been documented are weak (Dodd, 
Miaskowski, & Paul2001; Glover et al., 1995; Spiegel et al., 1994).  One explanation for 
these findings may be that the relationship between depressed mood and fatigue as well 
as the relationship between pain and fatigue occur through another symptom, namely 
sleep disturbance.  In other words, sleep disturbance mediates the relationship between 
depressed mood and fatigue as well as the relationship between pain and fatigue.           
Before beginning analyses aimed at explaining how sleep disturbance and other 
symptoms are related to one another, an understanding of the prevalence and severity of 
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sleep disturbance experienced within the cancer sample is warranted.  As described 
earlier, sleep disturbance is more completely and accurately assessed using both objective 
and subjective methodologies, as sleep disturbance may have different presentations 
depending on the measurement tools used.  Thus, the current study used both subjective 
and objective methodologies when evaluating sleep disturbance.   
Aims and HypothesesFor your reference, Time point 1 (T1) began on day 1 of 
participation in the study, which was 48 hours prior to chemotherapy administration.  
Time point 2 (T2) occurred on day 13,and then Time point 3 (T3) occurred during the last 
3 days of the study (days 22-24 for those with 7- and 21-day cycles and days 29-31 for 
those with 14- and 28-day cycles).   
Aim 1. The first aim of the study was to characterize the nature of sleep as 
experienced by cancer patients during acute treatment using subjective (diary and self-
report) and objective (actigraphy) ratings.  Sleep disturbance was examined via PSQI self 
report measure, sleep variables collected via sleep diaries (SOL, WASO, TST, SE), and 
the same sleep variables collected via actigraphy (SOL, WASO, TST, SE).  These 
variables were examined at T1 and T3, which were chosen as these are the only time 
points in which the primary study collected data via actigraphy and sleep diaries.  
Literature indicates that sleep disturbances are often over-estimated or under-estimated 
using subjective methodologies when compared to objective methodologies.  As such, we 
also aim to explore potential differences in subjective sleep diary data and objective 
actigraphy measurements of SOL, WASO, TST, and SE.   
 Hypothesis 1a. The majority (>50%) of participants would report clinically 
significant levels of all parameters of subjectively and objectively measured sleep 
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disturbance (as measured by a score of 8 or higher on the PSQI, SOL > 30 minutes, 
WASO > 30 minutes, TST < 8 hours, and SE < 85%) at T1.  These cutoff scores were 
selected to distinguish characteristics of good versus poor sleepers using a combination of 
the diagnostic criteria for insomnia (American Psychiatric Association, 2000) and 
literature that describes these parameters in healthy individuals with no sleep disturbance 
(Monk, Buysse, Rose, Hall, & Kupfer, 2000) as well as literature that describes sleep 
disturbance in a cancer population (Miaskowski & Lee, 1999).   
 Hypothesis 1b. The majority (>50%) of participants would continue to report 
clinically significant levels of all parameters of subjectively and objectively measured 
sleep disturbance at T3.  This is consistent with prior research that has demonstrated the 
persistence of sleep disturbance throughout chemotherapy treatment (Palesh et al., 2010; 
Savard et al., 2011).  
 Aim 2. The second aim of this study was to expand upon previous findings of 
positive relationships between the symptoms within the cluster (sleep disturbance, 
fatigue, pain, and depressed mood).  These variables were examined at T1 and T3, the 
only time points in which the primary study collected data via actigraphy.  Pearson’s 
product-moment correlational analyses were conducted to investigate bivariate 
relationships between sleep disturbance and the variables of interest (fatigue, pain, and 
depressed mood).  Sleep disturbance was measured via self report measure, sleep 
variables collected from sleep diaries, and sleep variables collected from actigraphy.     
 Hypothesis 2a. Subjective and objective measurements of sleep disturbance 
would positively correlate with fatigue, pain, and depressed mood at T1.   
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 Hypothesis 2b. Subjective and objective measurements of sleep disturbance 
would positively correlate with fatigue, pain, and depressed mood at T3.  
 Aim 3. The third aim of the study was to use confirmatory factor analyses to 
validate that the four symptoms identified from the literature are appropriately included 
as a single symptom cluster.    
 Hypothesis 3. A one factor solution would provide the best fit for the data.   
Aim 4. The fourth aim of the study was to test a prospective mediation model by 
which sleep disturbance mediates the relationship between pain + depressed mood and 
fatigue over three time points.  Time points were as follows: T1 will be day 1 of the study 
(48 hours prior to chemotherapy); T2 will be day 13 of the study; and T3 will be the last 
day of the study (this day varies between day 24 or day 31 depending on individual 
chemotherapy schedules).  These time points were chosen as recommended by Cole and 
Maxwell (2003) to allow for sufficient time between the measurement of each variable to 
allow for the relationship between variables to develop when testing a mediation model.  
Sleep disturbance will be measured via the PSQI as sleep variables calculated from sleep 
diary and actigraphy were collected only at T1 and T3.   
 Hypothesis 4. Sleep disturbance (measured by the PSQI) at T2 would mediate the 
relationship between pain + depressed mood at T1 and fatigue at T3.  Thus, first pain + 
depressed mood at T1 would significantly account for the variance in sleep disturbance at 
T2.  Second, sleep disturbance at T2 would significantly account for the variance in 
fatigue at T3.   
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CHAPTER 3: METHOD 
 
Participants 
 A secondary analysis of data collected from a pilot study of symptom clusters in 
cancer patients undergoing chemotherapy was conducted, using recommendations 
outlined by Clarke and Cossette (2000) that describe appropriate methods for conducting 
secondary analyses.  Participants in the primary study were a convenience sample (n= 
104) of oncology patients from Fox Chase Cancer Center (FCCC), a National Cancer 
Institute Comprehensive Cancer Center located in Philadelphia, Pennsylvania.  The 
specific objectives of the primary study were to 1) systematically examine the 
relationships between and among a group of physical symptoms (fatigue, insomnia 
symptoms, pain, and nausea) typically experienced during cancer chemotherapy to 
determine if they form one or more clusters; and 2) test alternative models of the impact 
of symptoms (and/or symptom clusters) on psychological and functional wellbeing.  
Participants who met the following inclusion criteria participated in the study: initiating 
or currently undergoing cancer chemotherapy for breast, lung, colorectal, prostate, 
gynecological, testicular, or bladder cancer or lymphoma; chemotherapy administered on 
a 7, 14, 21, or 28 day schedule; chemotherapy regimen contained at least one drug that is 
moderately or highly emetogenic; and ability to read and understand questionnaires that 
were delivered in English.      
 Individuals were excluded from participation in this study if they met any of the 
following exclusion criteria: treatment plan that included marrow or stem cell 
transplantation, interleukins, interferons, or tumor necrosis factor; hospitalized for more 
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than 24 hours during chemotherapy administration; a history of Chronic Fatigue 
Syndrome, other diagnosed chronic fatigue disorder, diagnosed sleep disorder, Chronic 
Pain Syndrome, or Sleep Apnea; initiated drug therapy within the past three weeks for 
anemia or depression; currently taking prescribed sleep medication; communication 
impairment; overt evidence of psychiatric disorder; or current participant in another study 
involving psycho-educational interventions.  These inclusion/exclusion criteria were 
chosen as they are consistent with other studies pertaining to the populations and 
constructs of interest, in order to aid in replication of findings as well as the ability to 
compare results of this study to previous research.   
Measures 
 Demographic sheet.  Information regarding participants’ age, gender, race, 
ethnicity, marital status, education, employment, and smoking status was collected. 
(Appendix A). 
 Clinical factors. Clinical information was gathered on each participant from the 
electronic medical records at FCCC (see Appendix B).  The information collected 
included: diagnosis; date of diagnosis; stage and status of disease (e.g. whether this was 
the initial diagnosis, recurrent disease, or metastatic disease); any treatment the patient 
received six months prior to participation in the study (e.g. surgery, radiation, and 
chemotherapy); the chemotherapy treatment regimen, including the name of the drug, the 
cycle, the days the drug is administered during the cycle, how many cycles planned to be 
given to the patient, and how many cycles the patient received up to and including the 
study period; and all drugs being given to the patient throughout the study period, 
including any start and stop  dates.  
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 The General Fatigue Scale. The General Fatigue Scale (GFS) is a 7-item 
questionnaire developed by the researchers of the primary study and used to measure 
fatigue intensity today and most days, highest intensity of fatigue in the 48 hours and past 
week, distress related to fatigue, and impact of fatigue on daily living.  Validity and 
reliability results include a Cronbach alpha reliability coefficient of 0.95, stability 
coefficient of 0.79, participation completion rate of 96% , significant sensitivity to 
change (t = 3.77, p = .001), and a factor analysis of one factor explaining 68% of the 
variance in fatigue. (Appendix C).   
 The Brief Pain Inventory. The Brief Pain Inventory (BPI) is widely used to 
measure pain in cancer patients (Cleeland, 1989; Cleeland et al., 1994).  The tool 
measures the existence and intensity of pain (worst, least, average, and current) on 0-10 
scale with 0 being “no pain” and 10 being “pain as bad as you can imagine” as well as the 
degree to which pain interferes with 7 domains of functioning (general activity, mood, 
walking ability, normal work, relations with other persons, sleep, and enjoyment of life).  
Evidence exists to support the reliability and validity of the measure.  Results include a 
Cronbach alpha reliability coefficient of 0.93 of the worst pain scale over a two-day 
period in a sample of 20 hospitalized patients with cancer and internal consistency of 
0.87 for the intensity scale (Lin & Ward, 1995; Serlin, Mendoza, Nakamura, Edwards, & 
Cleeland, 1995). (Appendix D).      
 The Profile of Mood States-Short Form. The Profile of Mood States-Short 
Form (POMS-SF) is a 30-item adjective checklist that measures subjective symptoms 
(i.e. depressed mood, anxiety, anger, confusion, fatigue, and vigor).  Items are scored on 
a 5-item likert-type scale ranging from “not at all” to “extremely” and subscale scores are 
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calculated by summing individual items.  This tool is well recognized as a sensitive, 
valid, and reliable measure (McNair, Lorr, & Droppleman, 1992).  While the primary 
study was interested in all subscales, the current study will use only the Depression 
subscale.  As this measure cannot diagnose or identify major depression disorder, 
depressed mood is a more appropriate identifier for the construct being assessed.   
(Appendix E). 
 Pittsburgh Sleep Quality Index (PSQI). The Pittsburgh Sleep Quality Index 
(PSQI) is 19 item subjective questionnaire used to evaluate sleep disturbances and related 
sequelae (Buysse et al., 1989).  While the questionnaire is designed for measurement over 
a 1 month period, (Beck & Schwartz, 2000) have tested a one-week version of the PSQI 
in 214 cancer patients with a Cronbach alpha of 0.81.  Responses are grouped into 7 
component scores that are weighted equally on a 0-3 scale, producing a global score that 
can range from 0-21.  The PSQI reliability is excellent (Cronbach’s alpha =0.85) and test-
re-test reliability and construct validity have been established (Backhaus, Junghanns, 
Broocks, Riemann, & Hohagen, 2002).  Higher scores indicate worse sleep quality with a 
clinical cut-off score of 8 has been suggested to differentiate good from poor sleepers in 
women with breast cancer (Carpenter & Andrykowski, 1998).  A cut-off score of 5 has 
been accepted and widely used in a general population (Buysse et al., 1989; Grandner, 
Kripke, Yoon, & Youngstedt, 2006).  Additionally, this measure has been found to be 
highly correlated with sleep diary values but not with actigraphy (Grandner et al., 2006). 
(Appendix F).   
 Actigraphy. Actigraphy provides an objective record of sleep quality and 
daytime activity related to body motion (Brown et al., 1990).  Data is obtained via 
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continuous non-invasive monitoring of activity using a wrist actigraph device.  Variables 
obtained include: SOL, WASO, TST, and SE.  Participants were instructed to push a 
small marker on the side when a) putting on the actigraph for the first time, b) when 
turning out the lights to go to sleep, and c) when getting out of bed in the morning.  These 
markers are used to discriminate day from night when performing the analysis.  
 Sleep diaries. Sleep diaries were collected in the primary study to be used as an 
adjunct to the objective data collected via actigrahy.  Specifically, participants completed 
the sleep diary while using the actigraph to provide confirmation of “lights off” and 
“lights on” in the event the participant forgets to press the event marker of the actigraph.  
Variables of SOL. WASO, TST, and SE were calculated from the sleep diaries and 
compared to the data collected by the actigraph. 
Procedure 
 The primary study used a single group prospective descriptive design.  
Observations were made of participants’ physical, functional, and psychological well 
being (components of quality of life).  The duration of participation was either 24 or 31 
days and FCCC was the only study site.  IRB approval was obtained from FCCC and data 
were collected from August 2003 to July 2005.  For the secondary analysis for this 
project, approval was also obtained from Drexel's Institutional Review Board.   
 Potential participants were identified by research staff with assistance from clinic 
staff and approached by telephone.  Individuals were enrolled if they met 
inclusion/exclusion criteria and provided written informed consent.  Because participants 
could have chemotherapy cycles lasting 7, 14, 21, or 28 days, data were obtained from 
participants on one of two possible schedules, depending on his or her chemotherapy 
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schedule.  These schedules were designed so that symptoms could be appropriately 
compared at the same time points within the chemotherapy cycle across participants with 
different length cycles.  As such, all participants were followed for approximately a one 
month period (24 or 31 days), and those with 7 or 14 day schedules were followed for 
multiple cycles of chemotherapy whereas those with 21 or 28 day schedules were 
followed for a single cycle of chemotherapy.  Both schedules are described in Table 1.  
While the primary study collected five time points of data, only three of these time points 
are of interest in this secondary analysis.  As such, the procedure for these three time 
points is described.     
 To remind you, T1 began on day 1 of participation in the study, which was 48 
hours prior to chemotherapy administration.  Baseline questionnaires gathering 
demographic information and gathering a variety of measures of physical and 
psychological symptoms were also administered.  Participants also kept sleep diaries and 
wore an actigraph for days 1, 2, 3, 4, and 5, removing the actigraph and stopping sleep 
diaries on day 6 of participation (3 days after chemotherapy treatment).  T2 occurred on 
day 13, when a packet of questionnaires (measuring physical and psychological 
symptoms) was completed by the patient over the phone with a research assistant.  Then 
T3 occurred during the last 3 days of the study (days 22-24 for those with 7- and 21-day 
cycles and days 29-31 for those with 14- and 28-day cycles).  Participants completed the 
same measures as those originally completed at baseline (with the exception of 
demographics).  Participants also completed sleep diaries and wore an actigraph for 3 
days.  Researchers also obtained clinical information from patients’ electronic medical 
records at the beginning and conclusion of the study.    
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Statistical Analysis 
 Statistical analyses were conducted using SPSS, AMOS, and Action W-2 analysis 
programs.  Intent-to-treat with last observation forward approach was utilized to handle 
missing data.  Prior to analysis of the study aims, actigraphy data were scored.  Down 
intervals (i.e. the time period in each 24 hour period that begins when an individual gets 
into bed with intention of sleeping and continues through until an individual decides to 
get up for the day) were determined and manually marked using event markers confirmed 
by visual inspection of the raw actigraph data.  When a large discrepancy between event 
markers and visual inspection of the raw actigraph data occurred, the time points at which 
a down event began and ended was determined via visual scoring, which occurred in the 
datasets of 3 individuals.  As a general rule for this visual scoring of down intervals, 
down start and end time were set close to times recorded in the corresponding sleep diary, 
provided that activity counts were not >500 following the start of rest for a 2 minute 
period and not >1000 for 5 minutes.  End of down interval was set at a point when 
activity increased to > 0 for a 5 minute period with 0 epochs scored as sleep.  As there is 
currently no universally accepted guideline for scoring actigraphy in a research setting, 
this general rule for manual scoring was adopted from a recent study investigating the 
accuracy of computer algorithms in scoring actigraphy (Boyne, Sherry, Gallagher, Olsen, 
& Brooks, 2012).  Automatic scoring of down intervals using the computer algorithm 
option was not utilized as the same study found less accurate results with the algorithm 
when compared to PSG recordings (Boyne et al., 2012).  After down intervals were 
marked, sleep/wake analysis was performed by the Action W-2 software to produce the 
sleep parameters (SOL, WASO, TST, SE).  For this analysis, epochs were set at 1 minute 
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and Cole Kripke (with rescoring rules) sleep scoring algorithm was selected.  As with the 
daily sleep diary generated sleep parameters, averages were then computed for the daily 
actigraphy generated sleep parameters at T1 and T3.   
After scoring of actigraphy data, processing of sleep diary data, and preliminary 
analyses of all variables of interest, Pearson product-by-moment correlational analyses 
were conducted to examine bivariate relationships among variables of interest using 
SPSS.  Due to the large number of analyses, a more stringent p value of .001 was utilized.     
Next, a confirmatory factor analysis was conducted using AMOS to validate the 
factor structure proposed.  Because no one statistic is universally accepted as an index of 
model adequacy, our interpretation of results emphasizes several measures of fit (Hu & 
Bentler, 1999).  The chi-square statistic is a global test of model's ability to reproduce the 
sample variance/covariance matrix.  However, it is important to recognize that 
significance levels are sensitive to sample size and departures for multivariate normality; 
thus, the chi-square statistic must be interpreted with caution in most applications.  The 
goodness of fix index (GFI) and adjusted goodness of fit index (AGFI) are measures of 
the relative amount of variance and covariance implied by the data set that are jointly 
accounted for by the model, with the AGFI differing from the GFI by adjusting for the 
degrees of freedom in the model.  GFI and AGFI range from 0 to 1 with values greater 
than 0.8 indicating a good fit.  Bentler's comparative fit index (CFI) ranges from 0 to 1 
with values greater than 0.95 indicating a good fit.  The root mean square error of 
approximation (RMSR) reflects the average residual obtained by taking the difference 
between the model-generated and sample variance/covariance matrices, with smaller 
values are associated with better fitting models and scores below 0.06 considered as 
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evidence of good fit.  Finally, the standardized root mean square residual (SRMR) ranges 
from 0 to 1 with values lower than 0.8 indicating a good fit.   
Finally, multistage regression and the Sobel test were completed to examine the 
proposed mediation model.  Two hierarchical regression analyses were conducted to 
examine both the a path and b path, which are required to for the joint significance test of 
α and β (see Figure 2).  Covariates included chemotherapy schedule, activity level, and 
employment status in both regressions.  In the first regression examining the a path, the 
effect of pain and depressed mood at T1 on the hypothesized mediator (sleep disturbance) 
at T2 was tested.  In the second regression examining the b path, the effect of the 
mediator at T2 on fatigue at T3 was tested, with both independent variables at T1 (pain 
and depressed mood) also entered into the model as predictors.  Two Sobel tests were 
then calculated to quantify the indirect effect of the mediation model.  One Sobel test 
calculation was needed for each independent variable, namely pain and depressed mood.          
It should be noted that the primary study changed the measurement tool of 
depressed mood during study recruitment in response to an IRB request to discontinue 
the use of a tool.  As such, approximately half of participants’ depressed mood symptoms 
were measured via the CESD (a widely used screening instrument to measured depressed 
mood on 1-60 scale, with higher score indicating the presence of more symptomology) 
during T2 while the later half reported depressed mood symptoms via the POMS-D 
during T2.  Only T2 was affected because the primary study was collecting both the 
POMS-D and CESD during T1 and T3.  Thus, for the current study, POMS-D data could 
be used to quantify depressed mood at T1 and T3 for all participants despite their time of 
participation.  In order to use all depressed mood data at T2 for all participants, separate 
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z-scores were created for data of both measures and then a depressed mood z-score was 
utilized in analyses.  For comparisons of depressed mood across time points, z scores 
were also calculated for T1 and T3 to allow for appropriate statistical comparisons.  
Statistical Power  
 In order to conduct analyses within the dataset with appropriate power, we 
referred to Fritz and MacKinnon (2007) and G*Power 3, a stand-alone power analysis 
program from statistical tests commonly used in behavioral research and available for 
free download on the World Wide Web (Faul, Erdfelder, Lang, & Buchner, 2007).  Due 
to the preliminary nature of Aims 1, we were not concerned with obtaining sufficient 
power.  For Aim 2, we used a more stringent alpha level of .01 due to the large number of 
analyses run.  For Aim 3, power is determined via a retrospective analysis using effect 
size, which is defined in terms of a null hypothesis and alternative hypothesis value of the 
root-mean-square error of approximation (RMSEA) index, sample size, and error rate 
(alpha level). For Aim 4, Fritz and MacKinnon (2007) recommend a sample size of 77 to 
test the significance of joint effects using an alpha level of .05, a medium effect size, and 
power of at least .80.  With G*Power 3, using an alpha level of .05, a medium effect size, 
and power of .90, 88 participants were needed.       
          
 
 
 
 
 
51 
 
 
CHAPTER 4: RESULTS 
 
Sample Characteristics 
 Sample characteristics were typical for Fox Chase population and the majority of 
cancer studies indentified in the literature.  Of the 104 participants, 82.7% (86) were 
female and 17.3% (18) were male.  Participants ranged in age from 26-80 years with a 
mean age of 55.59 years.  The majority of the sample self-identified as Caucasian 
(90.4%, N= 94), followed by African American (5.8%, N = 6), Hispanic/ Latino or Latina 
(1.9%, N = 2), Asian/Pacific Islander (1%, N = 1), and “More than 1 race or ethnicity” 
(1%, N= 1).  Most participants were married or living with a partner (77.9%, N = 81), 
with 11.5% (N = 12) reporting their status as divorced or separated, 6.7% (N = 7) 
widowed, and 3.8% (N = 4) single.  In terms of education level, 36.5% reported 
completing a 4 year college, 30.8% completed some college, 29.8% completed high 
school or technical school, and 2.9% completed some high school.  Slightly over half 
(51%, N = 53) reported that they were not currently working outside of the home during 
participation while the remainder (49%, N = 51) were engaging in some sort of 
employment outside their home.  Most participants reported their activity level since 
diagnosis to either 1) have no change (45.2%, N = 47) or a need to rest less than half of 
their normal daytime (43.3%, N = 45), while 11.5% (N = 12) reported a need to rest more 
than half of their normal daytime. (See Table 2).   
 Almost half of the sample had a diagnosis of breast cancer (43.3%, N = 45), 
followed by lung (26%, N = 27), ovarian, cervical, or endometrial (15.4%, N = 16), 
lymphoma (6.7%, N =7), colorectal (5.8%, N = 6), and prostate (2.9%, N = 3).  The 
52 
 
 
extent or severity of cancer disease was varied throughout the sample, with just over half 
(52.9%, N = 55) participating in the study during their initial diagnosis, 18.3% (N = 19) 
participating during a recurrent disease diagnosis, and 28.8% participating with 
metastatic disease.  The majority of the sample had 1-2 medical comorbidites (70.2%, N 
=73), with 20.2% (N = 21) reporting no known medical comorbidities and 9.6% (N = 10) 
reporting 3 or more medical comorbidities.  Looking at medications known to be sleep 
promoting or sleep disrupting, over half of the sample was taking both medications 
known to be sleep disrupting and sleep promoting (61.5%, N = 64) while over a quarter 
were taking one or more medications known to be sleep disrupting (29.8%, N = 31).  
Only 4 (3.8%) participants were taking only medications known to be sleep promoting 
and 5 (4.8%) participants were not taking any medications known to have any sleep side 
effects (see Table 3).       
Means and Normative Analyses 
 The sample means obtained from this study were compared with published mean 
values for each measure to determine how our sample compares to other samples of 
patients with cancer (see Table 4).  Our sample's scores varied across time points but 
were generally significantly different from normative values.  Global sleep quality was 
reported to be significantly more impaired at T1 but then significantly less impaired at T2 
and T3 when compared to the normative value.  Fatigue in our sample was significantly 
higher across all time points when compared to the normative mean whereas pain 
severity was reported to be significantly less across all time points compared to the 
normative mean.   Depressed mood was not significantly different for any time point 
compared to the normative means. 
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Reliability Check   
 Subscale analysis of the primary measures utilized in the present study were 
evaluated for internal consistency reliability, using Cronbach's α-coefficient.  Internal 
consistencies for the primary measures are presented in Table 5.  Reliability ranged from 
acceptable to excellent (.71-.95), demonstrating high internal consistency and allowing 
for the confident interpretation of measures.   
Preliminary Analyses 
 Preliminary analyses for descriptive statistics as well as normality and distribution 
where appropriate were conducted on the independent measures, proposed mediator, 
dependent measure, and demographic and clinical variables. Additionally, demographic 
and clinical variables were investigated as potential covariates by evaluating their 
relationships with the variables of interest (i.e., depressed mood, pain, sleep disturbance, 
and fatigue).  Due to the large number of analyses, a more stringent p value of .01 was 
utilized to address possible familywise error rates.  Those demographic and/or clinical 
characteristics that did have a significant relationship with the independent or proposed 
mediator were included as covariates in analyses of Aim 4 to control for their effect on 
the dependent variable.       
 All measures were found to be normally distributed.  Pain, depressed mood, sleep 
disturbance, and fatigue were not correlated with gender, ethnic identity, age, marital 
status, cancer type, extent of disease, medication use, or medical comorbidities (ps > .01), 
and therefore not included as covariates in analyses.  Employment status was 
significantly related to pain (as measured by BPI) at T3 as demonstrated via t-test 
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analysis, t(102) = 2.73, p = .008, with those not employed reporting significantly more 
pain, M = 2.07, SD = 2.57, relative to those who were working, M = 0.92, SD = 1.61.  
Chemotherapy schedule was significantly related to fatigue (as measured by GFS) at T2 
as demonstrated via ANOVA analysis, F(3, 92) = 3.79, p = .013, with eta squared = .12 
indicating a medium to large effect size.  Post hoc comparisons using the Tukey HSD test 
indicated that the mean fatigue level at T2 for those with 14 day chemotherapy schedules 
(M = 5.89, SD = 1.93) was significantly higher from those with 21 day chemotherapy 
schedules (M = 3.80, SD = 1.96).  There were no significant differences for those with 7 
or 28 day chemotherapy schedules.  Finally, activity level was significantly related to 
pain, depressed mood, and fatigue at multiple time points as demonstrated via multiple 
ANOVAs (all ps < .01 and medium to large effect sizes via eta squared).  Multiple post 
hoc comparisons using the Tukey HSD test generally indicated the most impairment 
across all three measures (pain, depressed mood, and fatigue) in those that required more 
than half of their day to rest, followed by those who required some but less than half of 
their day to rest, and the least impairment in those who did not require any extra time 
during their day to rest.  As such, employment status, chemotherapy schedule, and 
activity level were included as covariates in analyses conducted to evaluate hypotheses in 
Aim 4.        
Primary Analyses 
Aim 1. The first aim of the study was to characterize the nature of sleep as 
experienced by cancer patients during T1 and T3 using subjective (diary and self-report) 
and objective (actigraphy) ratings.  The following hypotheses were evaluated using 
percentages created from the means and standard deviations reported in Tables 4 and 6.  
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We also conducted exploratory analyses to examine potential differences in subjective 
sleep diary data and objective actigraphy measurements of SOL, WASO, TST, and SE.        
 Hypothesis 1a. We hypothesized that the majority (>50%) of participants would 
report clinically significant levels of sleep disturbance as measured by self report, diary, 
and actigraphy at T1.  Criteria for clinically disturbed sleep include PSQI 8 or greater or 
5 or greater (general populations and cancer specific criteria used), SOL > 30 minutes, 
WASO > 30 minutes, TST < 8 hours, SE < 85%.  While percentages are reported below, 
all means and standard deviations are reported in Tables 4 and 6.     
Subjective Sleep Disturbance. At T1, 66.3% of participants reported a total PSQI 
score of 8 or greater and 98.1 reported a total PSQI score of 5 or greater.  For sleep 
parameters via sleep diaries, 28.9% of participants reported an average SOL of greater 
than 30 minutes, 36.2% reported an average WASO of greater than 30 minutes, 91.5% 
reported an average TST of less than 8 hours, and 44.6 reported an average SE less than 
85%.    
 Objective Sleep Disturbance. At T1, actigraphy indicated that 22% of participants 
experienced an average SOL greater than 30 minutes,  68.9% experienced an average 
WASO greater than 30 minutes, , 79.1% experienced an average TST less than 8 hours, 
and 52.7% experienced an average SE of less than 8 hours.     
Hypothesis 1b. We hypothesized that the majority (>50%) of participants would 
continue to report clinically significant levels of sleep disturbance as measured by self 
report, diary, and actigraphy at T3.   
Subjective Sleep Disturbance. At T3, 37.5% of participants reported a PSQI total 
score of 8 or greater and 73.1% of participants reported a PSQI score of 5 or greater.  For 
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sleep parameters via sleep diaries, 21.7% participants reported an average SOL of greater 
than 30 minutes, 25.9% reported an average WASO of greater than 30 minutes,  74.1% 
reported an average TST of less than 8 hours, and 36.5% reported an average SE of less 
than 85%.         
 Objective Sleep Disturbance. At T3, actigraphy indicated that 26.8% of 
participants experienced an average SOL of greater than 30 minutes, , 57.3% experienced 
an average WASO greater than 30 minutes, , 85.4% of participants experienced an 
average TST less than 8 hours, and  44.4% experienced an average SE less than 85%.   
Thus, the hypothesis at T1 was supported on PSQI, WASO, and TST, but not 
supported for SOL or SE for both subjective and objective measurement of sleep 
disturbance.  At T3, the hypothesis was supported on the PSQI (for 5 or greater cut-off 
only),and TST, partially supported on WASO, but not supported on SOL or SE for 
subjective and objective measurement of sleep disturbance.     
 Planned Exploratory Analyses.  We conducted additional analyses to further 
explore potential significant differences in subjective sleep diary data and objective 
actigraphy measurements of SOL, WASO, TST, and SE at T1 and T3.  Using paired 
samples t-tests, TST measured via sleep diary and actigraphy at T3 was found to differ 
significantly, t(75) = 2.67, p = .009, with diaries indicating significantly more total sleep 
compared to actigraphy recording.  WASO values via sleep diary and actigraphy were 
also found to significantly differ at T1 and T3, t(86) = -4.59, p = .000 and t(79) = -4.69, p 
= .000 respectively, with diaries indicating significantly less WASO compared to 
actigraphy recordings.  Both SOL and SE did not significantly differ at T1 or T3. 
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 Thus, WASO and TST significantly varied at one or both time points depending 
on measurement tool (sleep diaries versus actigraphy), with diaries indicating more total 
sleep and less time awake after sleep onset compared to actigraphy recordings.  SOL and 
SE did not significantly differ by measurement tool.    
 Aim 2. The second aim of this study was to evaluate the bivariate correlations 
between sleep disturbance and the variables of interest (fatigue, pain, and depressed 
mood) at T1 and T3 using both subjective and objective measurements of sleep 
disturbance.  The following hypotheses were evaluated using correlation matrices (See 
Tables 7 through 10).   
 Hypothesis 2a. It was hypothesized that subjective and objective measurements of 
sleep disturbance would positively correlate with fatigue, pain, and depressed mood at 
T1.   
Subjective Sleep Disturbance. At T1, PSQI positively correlated with depressed 
mood, pain, and fatigue (all ps < .01).  SOL positively correlated with fatigue (r = .432, p 
< .01) but was not significantly correlated with depressed mood or pain (ps > .01).  TST 
negatively correlated with pain (r = -.320, p < .01), but was not significantly correlated 
with depressed mood or fatigue (ps > .01).  WASO and SE did not significantly correlate 
with depressed mood, pain or fatigue (ps >.01).   
Objective Sleep Disturbance. At T1, TST negatively correlated with pain (r = 
.432, p < .01), but was not significantly correlated with depressed mood or fatigue (ps > 
.01).  SOL, WASO, and SE were not significantly correlated with pain, depressed mood, 
or fatigue (all ps > .01).  
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 Hypothesis 2b. It was hypothesized that subjective and objective measurements of 
sleep disturbance would positively correlate with fatigue, pain, and depressed mood at 
T3.   
Subjective Sleep Disturbance. At T3, PSQI positively correlated with depressed 
mood, pain, and fatigue (all ps < .01).  SOL, WASO, TST, and SE did not significantly 
correlate with pain, depressed mood, or fatigue (all ps >.01).   
Objective Sleep Disturbance. At T3, WASO positively correlated with fatigue (r 
= .339, p < .01) and SE negatively correlated with fatigue (r = -.289, p < .01), but neither 
significantly correlated with pain or depressed mood (ps > .01).  SOL and TST were not 
significantly correlated with pain, depressed mood, or fatigue (all ps > .01).  
Thus, the hypotheses at T1 and T3 were supported on the PSQI.  However, the 
relationships between subjective and objective parameters of sleep and the other variables 
of interest (pain, depressed mood, fatigue) were inconsistent and few in number.  At T1, 
only two sleep diary variables (SOL and TST) correlated with fatigue or pain 
respectively, and no significant correlations were demonstrated between any of the sleep 
parameters measured with actigraphy and any of the symptoms in the cluster.  At T3, no 
significant correlations were demonstrated between any of the sleep parameters measured 
with sleep diary and any of the symptoms in the cluster but two objectively measured 
variables (WASO and SE) correlated with fatigue.  Additionally, the PSQI had higher 
correlations with the other symptom measures (e.g. pain, depressed mood, fatigue) than 
both the subjective and objective sleep parameters measured.      
Aim 3. The third aim of the study was to perform confirmatory factor analyses 
(CFA) to further substantiate that the four variables of interest (pain, depressed mood, 
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sleep disturbance, and fatigue) formed a single cluster of symptoms.  Goodness of fit 
indices included GIF and AGFI > 0.8, CFI > 0.95, RMSR < 0.06, and SRMR < 0.8.      
Hypothesis 3. It was hypothesized that the factor containing sleep disturbance, 
pain, depressed mood, and fatigue will be a good fit for the data at T1.     
 The single symptom cluster was a good fit for the data (Chi-square = 2.737 with 2 
df; GFI = .987; AGFI = .937; CFI = .991; RMSR = 0.60; and SRMR = .030).  The 
subjective measures of pain, depressed mood, sleep disturbance (measured via the PSQI), 
and fatigue appeared to fit a single symptom cluster.  See Figure 3 and Table 11 for 
standardized parameter estimates and unstandardized estimates. Unfortunately, 
retrospective power analyses indicated low power for this analysis, suggesting that these 
results should be interpreted with extreme caution.       
 Aim 4. The fourth aim of the study was to examine a model by which sleep 
disturbance mediates the relationship between both pain and depressed mood (entered 
simultaneously) and then fatigue over three time points.  In other words, pain and 
depressed mood taken together at T1 yields fatigue at T3 via sleep disturbance at T3.  
Preliminary analyses were conducted to ensure no violation of the assumptions of 
normality, linearity, multicollinearity, and homoscedasticity.  Covariates included 
chemotherapy schedule, employment status, and activity level in both regressions.  See 
Figure 2 for visual representation of model and Table 13 for Aim 4 results.     
Hypothesis 4. It was hypothesized that sleep disturbance (measured by the PSQI) 
at T2 would mediate the relationship between pain + depressed mood at T1 and fatigue at 
T3.  Thus, first pain + depressed mood at T1 would significantly account for the variance 
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in sleep disturbance at T2.  Second, sleep disturbance at T2 would significantly account 
for the variance in fatigue at T3.    
 The first regression examining the a path of depressed mood and pain at T1 on 
sleep disturbance at T2 was significant (depressed mood β = .29, p = .029 and pain β = 
.42, p = .014).  The second regression examining the b path of sleep disturbance at T2 on 
fatigue at T3 while also including depressed mood and pain at T1 as predictors was also 
significant (β = .11, p = .027) (See Table 12).  However, both Sobel tests failed to support 
the mediation model.  Sleep disturbance was not found to mediate the relationship 
between depressed mood and fatigue (z = 1.58, p = 0.157).  While approaching 
significance, sleep disturbance was also not significant in mediating the relationship 
between pain and fatigue (z = 1.67, p = 0.094).  Thus, the hypothesis that sleep 
disturbance mediates the relationship between pain + depressed mood and fatigue was not 
supported.  
Post Hoc Exploratory Analyses 
 Several analyses were conducted to further explore significant and nonsignificant 
findings from the primary analyses.  An alternative statistical approach was utilized to 
reexamine the proposed mediation model.  A simpler model to better understand our data 
was conducted and an alternative mediation model was examined.  Finally, changes in 
symptom experiences across time points were examined.           
Post Hoc Exploratory Analysis 1. Recent literature has suggested that 
bootstrapping methods may be superior to the Sobel test when testing intervening 
variable effects as they make no assumptions about the shape of the sampling distribution 
of the indirect effect and no standard error is needed to make the inference (Hayes, 2009; 
61 
 
 
Mackinnon & Fairchild, 2009; MacKinnon et al., 2007).  Bootstrapping is also shown to 
have higher power than the Sobel test through simulation research (Bollen & Stine, 
1992).  Considering the disparity in significance between the joint significance test and 
Sobel tests in Aim 4 as well as the identification of bootstrapping as more appropriate for 
statistically examining mediation, a post hoc exploratory analysis was conducted to 
investigate the proposed mediation model using resampling bootstrapping techniques.   
The bootstrapping technique generates an empirical representation of the 
sampling distribution of the indirect effect by treating the study sample as a 
representation of the population and repeatedly resampling (with replacement) as a means 
of mimicking the original sample process.  Once a resample is constructed, a and b are 
then estimated from the resampled dataset and the product of the path coefficients is 
recorded.  This process is repeated a large number of times (in this study, 5,000), 
providing 5,000 estimates of the indirect effect, thereby creating a distribution that 
functions as an empirical approximation of the sampling distribution of the indirect effect 
when taking a sample from the original population.  Percentage based confidence 
intervals of the size of the indirect effect are then generated using the a and b estimations 
from the resampled dataset.  Mediation is concluded when the 95% confidence intervals 
for the indirect effect do not contain zero (Preacher & Hayes, 2004), which is 
conceptually the same as rejecting the null hypothesis that the true indirect effect is zero 
with an alpha of 0.05.   
Mediation analyses based on 5000 bootstrapped samples using bias-corrected and 
accelerated 95% confidence intervals (Preacher & Hayes, 2004) showed that controlling 
for the effect of chemotherapy schedule (b = -.054, se = .207,  p = .794), activity level (b 
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= .744, se = .285,  p = .008), and employment status (b = -.501, se = .357,  p = .164), pain 
and depressed mood at T1 did have significant total effects on fatigue at T3 (Total Effect 
(TE)depressed mood= .218, se= .068, p= .002 and TEpain= .289, se= .090, p= ..002) but 
did not have significant indirect effects (Indirect Effect (IE)depressed mood = .039, se = 
.027, Lower Limit (LL) = -.002, Upper Limit (UL) = .103 and IEpain = .038, se = .032, 
LL = -.008, UL = .112) through the proposed mediator (sleep disturbance at T2).  Thus, 
bootstrapping confirmed the findings of the Sobel test, namely that sleep disturbance did 
not act as a mediator between pain + depressed mood and fatigue.   
 Post Hoc Exploratory Analysis 2. To further understand the nonsignificant 
result of the hypothesized mediation model in our sample, we conducted a post hoc 
exploratory analysis to examine a simpler model to describe our data.  A linear regression 
at T1 using simultaneous entry was conducted to examine pain, depressed mood, and 
sleep disturbance (measured via PSQI) as predictors of fatigue.  To account for covariates 
as in previous analyses, a hierarchical regression model was used, with chemotherapy 
schedule and employment status included in step 1.  Next, pain, depressed mood, and 
sleep disturbance were entered simultaneously in step 2 (See Table 13).  We 
hypothesized that pain, depressed mood, and sleep disturbance would all significantly 
account for variance in fatigue. 
 Results indicated that pain and depressed mood significantly accounted for the 
variance in fatigue (ps .010 and .013 respectively) but sleep disturbance failed to 
significantly account for variance in fatigue (p = .343).         
 Post Hoc Exploratory Analysis 3.  In an attempt to better explain our data, we 
considered a different mediation model that provided a more appropriate fit with our 
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findings.  In our data, bivariate correlations were significant between all variables of 
interest and a CFA analysis indicated that the model of a single symptom cluster made up 
of pain, depressed mood, sleep disturbance, and fatigue was a good fit for the data 
(however our analysis had low power).  These findings may lend support that all 
symptoms should remain in the cluster of interest and models attempting to explain how 
symptoms relate to one another.  When examining the variance in fatigue accounted for 
by the independent variables (pain, depressed mood, sleep disturbance) in a simpler 
simultaneous entry regression at T1, sleep disturbance (as measured by the PSQI) fails to 
account for variance in fatigue, whereas both pain and depressed mood do significantly 
account for variance in fatigue, which is contrary to our proposed mediation model but 
lends support to an adjusted hypothesized mediation model to explain how the symptoms 
interact.  Furthermore, a different model by Huang and Lin (2009) did not assess pain but 
found that depression mediated the relationship between sleep disturbance and fatigue in 
a homogenous sample of Taiwanese patients with hepatocellular carcinoma.  As such, we 
hypothesized that the experience of these symptoms in patients with cancer may be better 
explained by a model where sleep disturbance acts as the mediator and has a relationship 
with fatigue that is mediated by both depressed mood and pain.  See Figure 4 for revised 
mediation model.   
 Mediation analyses based on 5000 bootstrapped samples using bias-corrected and 
accelerated 95% confidence intervals showed that controlling for the effect of 
chemotherapy schedule (b = -.001, se = .223,  p = .997), activity level (b = 1.099, se = 
.287,  p < .001), and employment status (b = -.517, se = .375,  p = .171), sleep 
disturbance at T1 did have significant total effects on fatigue at T3 (TE= .144, se= .053, 
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p= .008) as well as significant indirect effects through the proposed mediators pain and 
depressed mood (IEpain = .060, se = .033, LL = .0117, UL = .1420 and IEdepressed 
mood = .023, se = .017, LL = .0004, UL = .0686) at T2.  Thus, the true indirect effects 
appear to be significantly different from zero, indicating mediation.  Pain and depressed 
mood appear to mediate the relationship between sleep disturbance and fatigue.     
Post Hoc Exploratory Analysis 4. We were also interested in better 
understanding how reported symptoms may have worsened or improved between T1, T2, 
and T3.  As such, we conducted four separate one-way repeated measures ANOVAs, one 
for each symptom measure (pain, depressed mood, sleep disturbance, and fatigue) to 
investigate changes in symptoms across time points.  After visual inspection of reported 
symptom means at each time point, we hypothesized that significant differences in 
symptom report across the time measurements would be found for sleep disturbance, but 
not pain, depressed mood, or fatigue.     
As hypothesized, there were no significant effects of time for pain, depressed 
mood, or fatigue (all ps > .01).  However, there was a significant effect of time for sleep 
disturbance scores as measured by the PSQI, Wilks Lambda = .521, F (2, 102) = 46.98, p 
< .001, multivariate partial eta squared = .479.  Post hoc comparisons indicated that time 
point 1 (M = 9.84, SD = .35) was significantly higher than at time points 2 (M = 7.23, SD 
= .342) and 3 (M = 7.19, SD = .35).  T2 and T3 did not significantly differ from one 
another.  Thus, sleep improved from T1 to T2 and remained improved at T3, but no 
change in symptom experience was reported for pain, depressed mood, or fatigue over 
time.  Some symptoms within the cluster (pain, depressed mood, and fatigue) appear to 
be stable across treatment while sleep appears to be more dynamic.     
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CHAPTER 5: DISCUSSION 
 
Review of Results 
 The purpose of this study was to characterize and evaluate the role of sleep 
disturbance within a cluster of symptoms commonly experienced in a sample of patients 
with cancer undergoing chemotherapy, and was demonstrated via four aims.  First, we 
aimed to describe subjective (diary and self report measurement) and objective 
(actigraphy) ratings of sleep disturbance as well compare the findings from the two 
methodologies.  As expected, sleep was generally poor at both time points but diary and 
actigraphy data provided discrepant information on some sleep parameter indices.  Next, 
we aimed to confirm previously demonstrated links between sleep disturbance and pain, 
depressed mood, and fatigue (Barsevick, Dudley, et al., 2006; Carpenter et al., 2004; 
Coleman et al., 2011; Dodd, Miaskowski, & Paul, 2001; Glover et al., 1995; Kim et al., 
2009; McMillan et al., 2008; Miaskowski & Lee, 1999; Spiegel et al., 1994).  Significant 
correlations emerged between the self report measure of sleep disturbance and pain, 
depressed mood, and fatigue at both time points.  In contrast, some sleep parameters 
measured with diary and actigraphy were correlated, while others were not.  CFA 
confirmed that sleep disturbance, pain, depressed mood, and fatigue were appropriately 
identified as a single factor, or symptom cluster, but low power makes for less confident 
interpretation.  Finally, , a prospective mediation model was tested to explain how these 
symptoms within the cluster related to one another.  The meditational relationship 
between pain + depressed mood at T1, fatigue at T3 and sleep disturbance at T2 was not 
confirmed as proposed.  However, a re-examination of findings did reveal that pain and 
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depressed mood at T2 acted as mediators between sleep disturbance at T1 and fatigue at 
T3.  We identified three themes from our analyses that enable us to better understand the 
significant contributions of our findings as well as provide direction for future research.    
Theme 1: Sleep is Poor in Patients with Cancer 
 It was not surprising that this study found significant sleep disturbances in a 
sample of patients with cancer undergoing chemotherapy as sleep problems in this 
population have been previously documented (Davidson et al., 2002; Palesh et al., 2010; 
Savard et al., 2011; Savard & Morin, 2001).  Due to multiple measurement 
methodologies and prospectivedesign, our results provide important information 
regarding the trajectory of the experience of sleep disturbances during the course of 
chemotherapy treatment as well as discrepancies in the report of sleep disturbance 
depending on the methodology used.   
 As projected, 66.3-98.1% (depending on cut-off criteria of 8 or 5) of our sample 
indicated poor global sleep quality (PSQI) at T1, with a mean score of 9.84.  Looking at 
T2 and T3, 43.3-71.2% and 37.5-73.1% respectively, continued to indicate poor global 
sleep quality but means reduced to 7.27 and 7.19 in our sample, which are below one 
threshold previously identified to indicate sleep disturbances in patients with cancer (8 or 
greater; Carpenter & Andrykowski, 1998) but still significant when compared to the cut 
off of 5 widely used in general population (Buysse et al., 1989; Grandner et al., 2006).  
Post hoc analyses found this reduction to be statistically significant, which is consist with 
previous research indicating that sleep disturbance mildly declines over time, but remains 
clinically significant (Palesh et al., 2010; Savard et al., 2011).  One hypothesis for this 
change may be that stress or anticipation related to an upcoming chemotherapy cycle may 
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contribute to poor sleep, with these factors naturally remitting after the treatment event, 
evidenced by slight reductions in sleep problems.  However, other perpetuating factors 
remain and serve to maintain the sleep disturbance, and it remains at a clinically 
significant level.   
 To gain a more comprehensive understanding of sleep disturbance in our sample 
beyond the PSQI, we also examined the averaged sleep parameters reported by sleep 
diary and recorded by actigraphy at T1 and T3.  Results indicated that average TST was 
below 8 hours per night for the majority of participants but SOL was less than 30 minutes 
by both measurements at both time points for the majority of participants, replicating 
findings using PSG in a similar sample of patients with cancer (Roscoe et al., 2011).  As 
such, it appears that while sleep is generally disrupted, SOL appears to be less of a 
problem in patients with cancer compared to other sleep disturbance parameters (e.g. 
WASO, TST).  These findings suggest that treatment for sleep disturbances in a cancer 
population may place greater emphasis on reducing nighttime awakenings and increasing 
total hours of sleep rather than reducing time to fall asleep.    
 Literature indicates that when diary and actigraphy recordings within individuals 
are compared, discrepancies are common.  In our sample, a discrepancy was noted for 
WASO, which was reported as significantly lower on diary report compared to 
actigraphy recordings.  Additionally, while SE was generally poor across both time points 
and the methods used to evaluate, our data did indicate that SE via sleep diary at T3 was 
slightly above the threshold used to identify sleep disturbance.  Looking to the literature, 
actigraphy is considered more accurate in absolute values of sleep disturbance in patients 
with cancer (Silberfarb et al., 1993; Wang, Chang, & Lin, 2010).  As such, our study 
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results suggest that WASO may be generally underreported in sleep diaries in this 
population and SE as measured via actigraph may be more accurate than the values 
calculated from subjective data.  However, it should be noted that our finding of 
subjective report of WASO as lower than our actigraphy recordings of WASO is not 
consistent with what is typically observed among healthy individuals with insomnia, who 
typically perceive their sleep to be more disrupted than what is documented via objective 
measurements (Means, Edinger, Glenn, & Fins, 2003).  It may be that patients with 
cancer who are experiencing insomnia specific sleep disturbances tend to experience less 
negative perceptions regarding their sleep difficulties compared to individuals with 
insomnia symptoms and no cancer diagnosis.  Further evaluation into the sleep related 
perceptions in patients with cancer may be warranted to better understand the 
presentation of sleep disturbances in this population.  
Finally, we noted that sleep as measured via sleep diary and actigraphy in our 
sample was consistently poor, even when PSQI scores were below the threshold of 8 
suggested by Carpenter and Andrykowski (1998) to identify poor sleep in patients with 
cancer.  Specifically, a self-reported mean PSQI score below the threshold of 8 was 
identified even though mean total hours of sleep reported via actigraphy and sleep diary 
were both below 8 hours, a threshold used to identify poor sleep.  Mean SE measured via 
actigraphy was also poor, below 85%.  In the general population, a PSQI cut-off score of 
5, rather than 8, is generally used to identify poor sleepers.  As such, our findings suggest 
that the cut-off score of 5 may be more appropriate to identify significant sleep 
disturbances in patients with cancer.  To appropriately identify poor sleep, future studies 
in patients with cancer may consider using a threshold of 5 when evaluating sleep 
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disturbances via the PSQI.  Clearly, patients with cancer experience significant sleep 
disturbances and this population would greatly benefit from appropriate evaluation and 
treatment for their sleep symptoms when indicated.   
Theme 2: Sleep Disturbance, Pain, Depressed Mood, and Fatigue Cluster Together  
 Multiple approaches exist to investigate symptom clusters and a strength of this 
study is the use of two approaches, namely bivariate correlations and CFA, to investigate 
the cluster consisting of sleep disturbance, pain, depressed mood, and fatigue.  A 
multitude of studies have demonstrated positive correlations between sleep disturbance 
has been found to be positively correlated with depression (Ancoli-Israel et al., 2006; 
Huang & Lin, 2009; McMillan et al., 2008; Mystakidou et al., 2007), pain (Coleman et 
al., 2011; Beck, Dudley, & Barsevick, 2005; McMillan et al., 2008; Mystakidou et al., 
2007; Sharma et al., 2011), and fatigue (Ancoli-Israel et al., 2006; Beck, Dudley, & 
Barsevick, 2005; Coleman et al., 2011; Hoffman et al., 2007; Huang & Lin, 2009; Liu et 
al., 2012; Wu, Davis, & Natavio, 2012) in patients with cancer.  As we predicted, our 
results replicated these findings, with significant correlations between the self report 
measure of global sleep disturbance and each of these symptoms, at T1 and T3.   
In an effort to extend these findings to sleep disturbance as measured by sleep 
diary and actigraphy recordings, we also examined bivariate relationships between the 
symptoms of interest (pain, depressed mood, fatigue) and the sleep parameters SOL, 
WASO, TST, and SE measured with both diary and actigraph.  The correlations between 
the symptoms of interest and sleep disturbances measured via diary and actigraphy are 
less consistent.  Relationships differed by measurement tool (diary versus actigraph) as 
well as by time measured (T1 vs T3).  Those relationships that were significant seem 
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consistent with the literature and our current understanding of symptom relationships.  
For example, there was a moderate positive correlation between diary reported SOL and 
fatigue as well as a moderate negative correlation between diary reported TST and pain at 
T1.  However, these relationships did not appear at T3, nor were they replicated in the 
data collected via actigraphy.  Similarly, there was a moderate positive correlation 
between actigraph calculated WASO and fatigue as well as a small negative correlation 
between actigraph calculated SE and fatigue at T3.  Once again, these relationships were 
not found at T1 or replicated in the diary data.  Failure to see similar relationships across 
time points may be due to the small but significant change observed in sleep disturbance 
from T1 to T3 as discussed above.  Failure to see similar relationships in both 
measurement methods at the same time point indicates that the sleep disturbance 
experience is complex; its relationship to the other symptoms that cluster together may be 
best understood with a tool (i.e. PSQI) that allows for the inclusion of the many 
individual sleep parameters that define it, including patient report of distress and 
impairment as a result of disturbed sleep, which is not evaluated with actigraphy or sleep 
diary parameters.     
Along with investigations into the bivariate relationships, CFA was used to 
confirm that sleep disturbance, pain, depressed mood, and fatigue were appropriately 
identified as a single factor, or symptom cluster; however, low power calls for caution in 
interpretation.  It would not be surprising that our analyses supported a factor structure 
made up of the four symptoms, as a multitude of investigations have identified 
relationships among pain, depressed mood, sleep disturbance, and/or fatigue in patients 
with cancer (Beck et al., 2005; Carpenter et al., 2004; Coleman et al., 2011; Hoffman et 
71 
 
 
al., 2007; Irwin et al., 2012; McMillan et al., 2008; Miaskowski & Lee, 1999; Sharma et 
al., 2011; Wang et al. 2008).  Numerous factor analyses have also investigated some of 
the four symptoms of interest and found factor structures indicating correlations and 
patterns of cohesion among multiple symptoms (Bender et al., 2008; Chen & Tseng, 
2006; Cleeland et al., 2000; Kim et al., 2008; Okuyama et al., 2003; Wang et al. 2008; 
Wang et al., 2006)  However, our finding is unique in that it is the first to systematically 
examine and potentially confirm this proposed symptom cluster of all four symptoms of 
interest (pain, depressed mood, sleep disturbance, and fatigue) in a sample of patients 
with cancer undergoing chemotherapy.  Our results potentially indicate a useful 
framework to guide the identification of these commonly occurring symptoms in clinical 
practice, barring additional replication studies with appropriate power to confirm the 
single factor.  Specifically, the presence of one symptom may warrant investigation into 
the other symptoms within the cluster in both clinical and research settings.  This 
understanding of the correlations between symptoms in the cluster may lead to more 
complete patient care in symptom management, improving treatment outcomes as well as 
quality of life.   
Theme 3: Significance of Mediation Model   
Moving beyond the confirmation of the interrelationships among symptoms, we 
then examined a prospective mediation model in an attempt to explain how these 
symptoms within the cluster were related to one another.  It was hypothesized, but not 
confirmed, that that the relationship between pain + depressed mood at T1 and fatigue at 
T3 would be mediated by sleep disturbance at T2.  Multiple statistical approaches were 
utilized to examine this model, as the original hypothesized method (joint significance 
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test and Sobel test) provided discrepant results.  Bootstrapping confirmed the 
nonsignificant result of the Sobel test, indicating that our model was not an appropriate fit 
for the data.         
In an attempt to understand our nonsignificant result, we then conducted a post 
hoc linear regression with simultaneous entry at baseline to better understand the 
relationships between the symptoms.  Interestingly we found that while pain and 
depressed mood did significantly account for the variance in fatigue, sleep disturbance 
did not.  This was in direct contrast to our expectations that sleep disturbance would 
significantly account for the variance in fatigue, due to its placement in our proposed 
mediation pathway and the theoretical requirements for mediation to occur.  Clinically, 
this is an unexpected but important finding, namely that sleep and fatigue appear to not 
be directly related.  In contrast, this nonsignificant finding suggested that the relationship 
between sleep disturbance and fatigue may instead occur through one or more other 
symptoms, namely depressed mood and pain.  Considering the bidirectional relationships 
between pain and sleep disturbance (Coleman et al., 2011; McMillan et al., 2008; Sharma 
et al., 2011) as well as depression and sleep disturbance (Carpenter et al., 2004; Irwin et 
al., 2012; McMillan et al., 2008), it was reasonable that the placement of these symptoms 
in our mediation model could be appropriately reversed and continue to describe 
previously demonstrated relationships.  The mediation model described by Huang and 
Lin (2009), which indicated that depression mediated the relationship between sleep 
disturbance and fatigue, provided additional support for our differing approach in 
interpreting the sleep – depressed mood relationship in our model.  As such, we 
conducted a post hoc analysis using bootstrapping to examine a different prospective 
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mediation model, namely that pain and depressed mood at T2 acted as mediators between 
sleep disturbance at T1 and fatigue at T3.   
Our revised model was supported; specifically, we found support for sleep 
disturbance at T1 accounting for variance in both pain and depressed mood at T2.  
Furthermore, we found support for pain and depressed at T2 mood accounting for 
variance in fatigue at T3.  This role of pain and depressed mood as mediators between 
sleep disturbance and fatigue indicates that one reason sleep disturbance is related to 
fatigue is because pain and depressed mood mediate the relationship between sleep 
disturbance and fatigue.  It is important to point out that our model is not suggesting that 
one symptom predisposes a person to experience another symptom, as in the research 
suggesting that sleep disturbance may predispose one to depressed mood (Perlis et al., 
2006).  The experience of all four symptoms was found to be significant at baseline in 
our sample; therefore, no casual relationships of one symptom causing another symptom 
can be inferred.  Instead, our model seeks to further understand how the experience of 
one or more symptoms in the cluster relates to the experience of other symptoms within 
the cluster over a month period during chemotherapy.  In other words, the experience of 
sleep disturbance at T1 is related to pain and depressed mood at T2, which in turn, is 
related to fatigue at T3. 
We cautiously comment that these findings may provide important treatment 
considerations.  The use of a prospective design to examine the proposed mediation 
model is significant in that this is the first study, to our knowledge, to investigate the 
experience of this commonly occurring symptom cluster over time, rather than a cross 
sectional design.  As such, our findings provide valuable insight into the prospective 
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experience of the interrelationships among the symptoms within the cluster, addressing 
how patients with cancer undergoing chemotherapy that present with this symptom 
cluster might expect their symptom experience to occur for their treatment duration.  
Furthermore, our results may suggest that strategies targeting pain management and 
improving depressed mood by decreasing sleep disturbance may also contribute to 
decreased fatigue.  For example, reducing sleep disturbance may also improve pain 
symptoms and reduce depressed mood in an individual, which then contributes to less 
fatigue.  As such, we recommend the investigation of this intervention strategy in a 
prospective way to better understand its utility in a cancer population and determine what 
symptom management strategies have the most beneficial impact on the symptom cluster 
experience as a whole.  However, we understand that the occurrence of symptoms in 
patients with cancer is extremely complex and this model may be one potential avenue to 
improve treatment, but may also be viewed for its insight into mechanistic properties of 
the symptom experience.  In this way, by identifying an additional way in which 
symptoms relate to one another in this population, our findings can promote additional 
ideas for future studies aimed at ideal treatment of symptom suffering in patients with 
cancer.   
Implications 
 In our study, subjective and objective methodologies indicated that sleep 
disturbances are significant in patients with cancer undergoing chemotherapy.  While 
actigraphy appeared to provide a more precise measurement of specific sleep parameters, 
subjective methodologies (e.g. sleep diaries and the PSQI) appeared to be appropriate for 
evaluating and characterizing sleep disturbances in a cancer population.  As such, our 
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findings suggest that self report measures (which are less expensive and easier to obtain 
compared to objective methodologies) can be used with confidence in the evaluation of 
sleep disturbances in a clinical setting.     
 Considering the role of sleep disturbance within other symptoms experienced in 
patients with cancer, our findings confirmed significant clustering of pain, depressed 
mood, sleep disturbance, and fatigue in patients with cancer undergoing chemotherapy.  
As such, patients with cancer may benefit from evaluation of all four symptoms in the 
event that one symptom is observed, due to our understanding of these symptoms 
clustering together in the cancer population.  Our mediation model whereby pain and 
depressed mood mediated the relationship between sleep disturbance and fatigue then 
provided additional clinical information to guide evaluation and treatment of these 
symptoms in a cancer population.  Specifically, when this symptom cluster is identified 
in a patient with cancer, we cautiously suggest that our mediation model indicates that 
specific treatment strategies aimed at treating one symptom may also indirectly treat one 
or more other symptoms.  For example, pain and depressive symptoms may be reduced 
by decreasing sleep disturbances, and this may also contribute to improved fatigue levels.  
It may be that patients could experience a reduction in all of their symptoms through an 
intervention aimed at a single symptom.  We recommend future prospective 
investigations to examine this type of intervention on pain, depressed mood, sleep 
disturbance, and fatigue in a cancer population.  We also recommend re-examination of 
these symptoms with a study of longer duration to gather a more comprehensive 
understanding of the symptom experience and interrelationships for the entire duration of 
treatment.        
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Limitations  
 Although our results are promising, it is important to recognize that this was a 
secondary analysis of data, which presents methodological and practical challenges, even 
in the case of a parent study with a strong design.  Specifically, missing data due to drop 
out from the parent study may act as selection bias, with those discontinuing participation 
potentially because they are more sick or experiencing more symptoms compared to 
those who completed all study time points.  While this was handled in our study with 
intent-to-treat method, last observation carried forward, and analyses using the intent-to-
treat data versus exclusion of participants with missing data were compared with no 
differences, selection bias may still have occurred, limiting generalizability.  As with the 
parent study, we were also limited by sample size and representativeness of the study 
sample, with the majority of the sample identifying as married female Caucasians, which 
further limits generalizability.  We were also limited by the measurement tools selected in 
the parent study for each symptom of interest.  Naturally, our aims vary from the parent 
study, and we may prefer different tools when examining constructs.  For example, we 
were unable to examine insomnia severity, rather than or in conjunction with sleep 
disturbances due to the primary study’s use of the PSQI and no other insomnia specific 
tool (e.g. Insomnia Severity Index).  Similarly, we could only examine depressed mood 
rather than depression due to the discontinuation of the CESD and replacement with the 
POMS-D.   
Thinking about the timing of data collection, we were limited by the data 
collection time points of the parent study, thereby unable to examine objective 
measurements of sleep disturbance (actigraphy) in the mediation model proposed.  
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Specific data variables collected via the parent study was also a limitation for our 
secondary analysis, as we were unable to distinguish patients who were prior to their first 
ever chemotherapy at T1 versus patients who have been receiving chemotherapy prior to 
enrollment in the study and were prior to their next anticipated chemotherapy cycle at T1.  
As such, we are unable to comment on the experience of the symptom cluster prior to 
chemotherapy compared to the experience during chemotherapy.  Similarly, the length of 
the study does not allow for proper examination of the stability of symptoms over the 
entire chemotherapy treatment course.  Finally, while the primary study collected data 
fairly recently (2003-2005), specific medical advances in chemotherapy treatment or 
symptom management may have occurred since data collection that our secondary 
analyses cannot consider in our investigation.   
In light of these limitations, we acknowledge that further research using original 
study design is needed to examine the experience of sleep disturbance and our proposed 
mediation model prospectively in other samples of patients with cancer, with careful 
consideration of investigation for the entire treatment trajectory and using the most 
appropriate tools for symptom measurement.  Specifically, the use of objective 
methodologies and tools that can appropriately identify insomnia symptoms and 
depression may contribute to our understanding of the symptom cluster experience.  
Measurement of the symptom cluster throughout the entire treatment trajectory will 
provide information on the stability of symptoms and the stability of relationships among 
symptoms.  Finally, examination of the symptom cluster with other samples of patients 
with cancer will allow for better generalizability of findings.       
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Figure 1. Classic Mediation Model  
 
 
 
Note: MacKinnon, Fairchild, and Fritz (2007) argue that path c is not a necessary 
component to demonstrate mediation.   
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Figure 2. Proposed Mediation Model  
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Figure 3. Results of the CFA Model 
 
 
 
 
Root mean square error of approximation = .060; Chi-Square = 2.737; degrees of 
freedom = 2. e = error.   
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Figure 4. Revised Mediation model 
 
 
 
 
M = mediator 
X = independent variable  
Y = dependent variable 
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Table 1: Procedure Schedules 
 
 
 
Schedule 1: 7- and 21-day cycles 
Study Day Procedure 
Day 1 Complete Time 1 questionnaires (PSQI, BPI, POMS-D, GFS, 
demographics and clinical characteristics) 
 
 Begin sleep diary and actigraphy 
Days 2-5 Continue sleep diary and actigraphy 
 
Day 6 Remove Actigraph and stop sleep diary  
 
Day 13 Complete Time 2 questionnaires (PSQI, BPI, POMS-D, GFS) 
 
Day 22 Begin sleep diary and actigraphy  
 
Day 23 Continue sleep diary and actigraphy  
 
Day 24 Complete Time 3 questionnaires (PSQI, BPI, POMS-D, GFS)  
 
Continue sleep diary and actigraphy 
 
Schedule 2: 14- and 28- day cycles 
Study Day Procedure 
Day 1 Complete Time 1 questionnaires (PSQI, BPI, POMS-D, GFS, 
demographics and clinical characteristics)  
 
Begin sleep diary and actigraphy 
Day 2-5 Continue sleep diary and actigraphy 
 
Day 6 Remove Actigraph and stop sleep diary  
 
Day 13 Complete Time 2 questionnaires (PSQI, BPI, POMS-D, GFS) 
 
Day 29 Begin sleep diary and actigraphy 
 
Day 30 Continue sleep diary and actigraphy 
 
Day 31 Complete Time 3 questionnaires (PSQI, BPI, POMS-D, GFS) 
 
Continue sleep diary and actigraphy  
 
Scale Abbreviations: General Fatigue Scale (GFS), Brief Pain Inventory (BPI), Pittsburgh 
Sleep Quality Index (PSQI), Profile of Mood States- Depression Subscale (POMS-D) 
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Table 2. Demographic Characteristics of Sample 
 
 
Characteristic Total  Sample N= 104 
n                                    % 
Gender   
   Male 18 17.3 
   Female 86 82.7 
Race or ethnicity   
   African American 6 5.8 
   Asian/Pacific Islander 1 1.0 
   Hispanic/Latino or Latina 2 1.9 
   White 94 90.4 
   More than 1 race or ethnicity 1 1.0 
Marital Status   
   Single 4 3.8 
   Married or living with a partner 81 77.9 
   Separated or divorced 12 11.5 
   Widowed 7 6.7 
Education   
   Some high school 3 2.9 
   Completed high school or technical school 31 29.8 
   Some college 32 30.8 
   Completed college 38 36.5 
Employment Status   
   Working outside home  51 49.0 
   Not working outside home 53 51.0 
Current Activity Level   
   No change in activity level during day 47 45.2 
   Need to rest <  ½ normal daytime                       45 43.3 
   > ½ normal daytime required to rest  12 11.5 
Age (years)   
   Mean                  55.59 
   SD                  11.54 
Note. Because of rounding, not all percentages total 100. 
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Table 3. Clinical Characteristics of Sample 
 
 
Characteristic Total  Sample N= 104 
n                                    % 
Type of Cancer   
   Breast 45 43.3 
   Colorectal 6 5.8 
   Lung 27 26 
   Lymphoma 7 6.7 
   Ovarian, cervical, or endometrial 16 15.4 
   Prostate 3 2.9 
Extent of Disease    
   Initial Diagnosis 55 52.9 
   Recurrent Disease 19 18.3 
   Metastatic Disease 30 28.8 
Medical co-morbidities   
   None 21 20.2 
   1-2 co-morbidities 73 70.2 
   3 or more co-morbidities 10 9.6 
Medications   
None 5 4.8 
Sleep promoting 4 3.8 
Sleep disrupting 31 29.8 
Both sleep promoting and sleep disrupting 64 61.5 
Note. Because of rounding, not all percentages total 100. 
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Table 4. Sample Means Compared to Published Means 
 
 
 Variable   Sample Mean and           Normative Mean and        T-test 
    Standard Deviation          Standard Deviation  
 
       
Pittsburgh Sleep Quality Index 
1    M = 8.15 (4.70) 
 Time Point 1  M = 9.84 (3.56)     t(103) = 4.83** 
 Time Point 2  M = 7.27 (3.49)     t(103) = -2.57* 
 Time Point 3  M = 7.19 (3.55)     t(103) = -2.76** 
     
General Fatigue Scale 
2     M = 3.3 (1.8) 
 Time Point 1  M = 3.87 (2.12)     t(103) = 2.73** 
 Time Point 2  M = 4.11 (2.03)     t(103) = 4.06** 
 Time Point 3  M = 3.90 (2.11)     t(103) = 2.90** 
  
 
Profile of Mood States- 
    Depression subscale
3    M = 7.04 (4.42) 
 Time Point 1  M = 7.24 (2.71)     t(103) = 0.75 
 Time Point 2  M = 7.81 (3.18)     t(63) = 1.95 
 Time Point 3  M = 7.24 (2.82)     t(103) = 0.73 
  
 
Center for Epidemiological  
    Studies-Depression
4    M = 20.8 (10.70) 
 Time Point 2  M = 28.80 (7.45)     t(39) = 6.79** 
  
Brief Pain Inventory
5     
M = 4.44 (2.68) 
   
 
 
 Time Point 1  M = 1.57 (2.13)     t(103) = -13.74** 
 Time Point 2  M = 1.63 (2.10)     t(103) = -13.66** 
 Time Point 3  M = 1.50 (2.22)     t(103) = -13.46** 
  
 
*p<.05 
**p<.01 
1
 (Beck, Schwartz, Towsley, Dudley, & Barsevick, 2004). Means are based on a diverse sample of patients 
with cancer receiving treatment.   
2 
(Barsevick et al., 2004)Means are based on patients with cancer initiating chemotherapy and/or radiation 
therapy.   
3
 (Baker, Denniston, Zabora, Polland, & Dudley, 2002). Means are based on patients with cancer awaiting 
bone marrow transplant. 
4
 (McMillan et al., 2008). Means are based on outpatients with cancer receiving treatment. 
5
(Tittle, McMillan, & Hagan, 2003).  Means are based on surgical and medical patients with cancer. 
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Table 5.  Cronbach’s Alpha for Primary Scales 
 
 
 
 
Variable      Cronbach’s Alpha       # of Items 
Pittsburgh Sleep Quality Index    .71   9 
  
 
General Fatigue Scale     .95              7 
 
Profile of Mood States Short Form:  
 Depression subscale    .79   5 
 
Center for Epidemiological Studies: 
 Depression      .74   20 
 
Brief Pain Inventory     .94   4   
 
All values calculated from measures collected at T1, with the exception of the CES-D, which was calculated at T2.   
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Table 6.  Diary and Actigraphy Sleep Characteristics (Aim 1) 
 
 
 
  
 
Note. Mean values marked with * exceed cut-off scores identified in text for sleep disturbance parameters.   
 
 
 
 
Diary T1 
(5 Day Average) 
 
Actigraphy T1 
(5 Day Average) 
Diary T3 
(3 Day Average) 
Actigraphy T3 
(3 Day Average) 
Total Sleep Time  Total Sleep Time  Total Sleep Time  Total Sleep Time  
Mean = 6.97 hours* Mean = 6.7 hours* Mean = 7.2 hours* Mean = 6.82 hours* 
SD = 1.17 hours SD = 1.58 hours SD = 1.23 hours SD = 1.28 hours 
Range = 4.2 – 9.2 hours Range = 2.02 - 10.3 hours Range = 4.67 – 10.68 hours Range = 3.5 – 9.57 hours 
    
Sleep Onset Latency (minutes) Sleep Onset Latency (minutes) Sleep Onset Latency (minutes) Sleep Onset Latency (minutes) 
Mean = 26.43 Mean = 27.06 Mean = 20.57 Mean = 21.93 
SD = 24.71 SD = 30.09 SD = 22.39 SD = 25.96 
Range = 2.00 – 120.00 Range = 0.00 – 180.50 Range = 1.00 – 113.00 Range = 0.00 – 139.50 
    
Wake After Sleep Onset (minutes) Wake After Sleep Onset (minutes) Wake After Sleep Onset (minutes) Wake After Sleep Onset (minutes) 
Mean = 30.77* Mean = 61.33* Mean = 24.06 Mean = 54.57* 
SD = 31.48 SD = 58.32 SD = 28.36 SD = 50.13 
Range = 1.00 – 178.00 Range = 8.80 – 309.40 Range = 0.00 – 122.00   Range = 4.50 – 292.67 
    
Sleep Efficiency  Sleep Efficiency  Sleep Efficiency  Sleep Efficiency  
Mean = 83.74%* Mean = 81.19%* Mean = 86.59% Mean = 83.10%* 
SD = 9.45% SD = 14.61% SD = 9.28% SD = 12.30% 
Range = 55.93% - 97.60% Range = 30.23 – 97.16% Range = 57.17% - 98.66% Range = 43.21% - 98.02% 
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Table 7.  Correlation Matrix of Subjective Sleep Disturbance, Depressed Mood, Pain, and Fatigue at T1 (Aim 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  * p < .01 
  Pittsburgh Sleep Quality Index (PSQI) 
  Brief Pain Inventory (BPI) 
  General Fatigue Scale (GFS) 
  Profile of Mood States- Depression (POMS-D) 
   SOL, WASO, TST, SE as measured via sleep diaries 
 
 
 
 
 PSQI SOL WASO TST SE BPI GFS POMS-D 
PSQI -        
SOL .313* 
 
-       
WASO .098 .024 -      
TST -.210 -.059 -.153 -     
SE -.280 -.495* -.549* .520* -    
BPI .436* -.065 .007 -.320* -.078 -   
GFS .374* .432* .042 -.078 -.216 .479* -  
POMS-D .371* .264 .187 -.234 -.235 .352* .474* - 
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Table 8.  Correlation Matrix of Subjective Sleep Disturbance, Depressed Mood, Pain, and Fatigue at T3 (Aim 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  * p < .01 
  Pittsburgh Sleep Quality Index (PSQI) 
  Brief Pain Inventory (BPI) 
  General Fatigue Scale (GFS) 
  Profile of Mood States- Depression (POMS-D) 
`  SOL, WASO, TST, SE as measured via sleep diaries 
 
 
 
 
 PSQI SOL WASO TST SE BPI GFS POMS-D 
PSQI -        
SOL .304* 
 
-       
WASO .179 -.054 -      
TST -.210 -.023 -.098 -     
SE -.088 -.429* -.611* .496* -    
BPI .403* .190 .075 -.193 -.244 -   
GFS .297* .240 .004 .081 -.086 .575* -  
POMS-D .326* .104 -.076 -.104 -.054 .439* .549* - 
101 
 
 
Table 9.  Correlation Matrix of Objective Measures of Sleep Disturbance with Subjective Measures of Depressed Mood, Pain, 
and Fatigue at T1 (Aim 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              * p < .01 
   Brief Pain Inventory (BPI) 
   General Fatigue Scale (GFS) 
   Profile of Mood States- Depression (POMS-D) 
   SOL, WASO, TST, SE as measured via actigraphy 
 
 
 
 
 
 
 
 
SOL WASO TST SE BPI GFS POMS-D 
SOL -       
WASO .163 -      
TST -.488* -.336* -     
SE -.684* -.699* .717* -    
BPI .026 .035 -.334* -.119 -   
GFS .104 .115 -.121 -.129 .479* -  
POMS-D -.041 .008 -.071 .043 .352* .474* - 
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Table 10.  Correlation Matrix of Objective Measures of Sleep Disturbance with Subjective Measures of Depressed Mood, Pain, 
and Fatigue at T3 (Aim 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
    
   * p < .01 
   Brief Pain Inventory (BPI) 
   General Fatigue Scale (GFS) 
   Profile of Mood States- Depression (POMS-D) 
   SOL, WASO, TST, SE as measured via actigraphy 
  
 
 
 SOL WASO TST SE BPI GFS POMS-D 
SOL -       
WASO .194 -      
TST -.321* -.426* -     
SE -.553* -.849* .680* -    
BPI .015 .255 -.177 -.265 -   
GFS .061 .339* -.051 -.289* .575* -  
POMS-D -.141 .039 -.016 -.004 .439* .549* - 
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Table 11. Standardized and Unstandardized Coefficients for CFA (Aim 3) 
 
 
 
Observed Variable  Factor   β  B  SE   
Pain (BPI)   1   .661  1.0 
Sleep disturbance (PSQI)  1   .587  1.47  .331  
Fatigue (GFS)   1   .715  1.08  .218  
Depressed mood (POMS-D) 1   .613  1.18  .256 
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Table 12. Results from Hierarchical Linear Regressions (Aim 4) 
 
 
 
     R² F B SE Beta  t p   
Results for a path 
Step 1 
 Chemotherapy schedule    -.44 .42 -.10 -1.03 .305 
 Activity level     .61 .52 -.12 1.16 .251 
 Employment status    -.93 .70 -.13 -1.33 .187 
     .407 15.62 
 
Step2 
 Chemotherapy schedule    -.28 .40 -.07 -.71 .482 
 Activity level     -.11 .52 -.02 -.21 .832 
 Employment status    -.90 .66 -.13 -1.38 .172 
 Pain time point 1     .42 .17 .25 2.52 .014 
 Depressed mood time point 1   .29 .13 .22 2.22 .029 
     .182 4.35 
Results for b path 
Step 1 
 Chemotherapy schedule    -.18 .23 -.07 -.753 .453 
 Activity level     1.24 .29 .40 4.33 .000 
 Employment status    -.57 .38 -.14 -1.50 .140 
     .213 9.05 
 
Step2 
 Chemotherapy schedule    -.03 .20 -.01 -.14 .888 
 Activity level     .73 .26 .23 2.67 .007 
 Employment status    -.45 .33 -.11 -1.36 .179 
 Pain time point 1     .18 .07 .23 2.72 .008 
 Depressed mood time point 1   .26 .09 .26 3.03 .003 
 Fatigue time point 3                                                      .11  .05 .19 2.25 .027      
.440 12.69 
 
________________________________________________________________________ 
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Table 13. Results from Hierarchical Linear Regressions (Post Hoc Exploratory 
Aim) 
 
 
 
     R² F B SE Beta  t p   
Step 1 
 Chemotherapy schedule    -.25 .21 -.10 -1.16 .250 
 Activity level     1.66 .27 .53 6.10 .000* 
 Employment status    -.03 .36 -.01 -.08 .939 
     .556 14.93 
 
Step2 
 Chemotherapy schedule    -.15 .19 -.06 -.76 .449 
 Activity level     1.17 .26 .37 4.55 .000* 
 Employment status    -.00 .32 .00 -.01 .997 
 Pain time point 1     .23 .09 .23 2.65 .010* 
 Sleep disturbance time point 1   .05 .05 .08 .952 .343 
 Depressed mood time point 1   .20 .06 .25 3.04 .003* 
     .688 14.55 
________________________________________________________________________ 
* p < .05 
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APPENDIX A: Demographics Sheet 
 
Please tell us about yourself.    Date you complete this: _______ 
 
1. Your age: ____ years 
 
2. Your sex: (circle one) 
 Male  Female 
 
3. Your ethnic background (circle one) 
 Hispanic or Latino     Not Hispanic or Latino     Unknown 
 
4. Your racial background (circle one) 
 American Indian/Alaska Native  Asian 
 Native Hawaiian or Other Pacific Islander Black or African American 
 White      More than one race 
 Unknown 
 
5. Your marital status (circle one) 
 Single (never married)   Separated or Divorced 
 Widow or Widower    Married 
 
6. Highest grade of school you completed: 
 8
th
 grade or less    Some high school 
 High school graduate or GED  Technical school graduate 
 Some college     College graduate 
 
7. Are you currently employed (work for money)? 
 No  Yes 
 
8. Do you work outside your home? 
 No  Yes 
 
9. Do you engage in volunteer or other activities that you would view as work? 
 No  Yes 
 
10. If you answered yes to any of the questions above, how many hours a week are you 
scheduled to work or volunteer? _______ 
 
11. Are you planning to decrease your work or volunteer time because of your cancer or 
treatment? 
 No  Yes 
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12. If you do not work, are you: 
 Retired   Disabled  A Student 
 Looking for work  Taking time off A Homemaker 
 Caring for family member(s)   
 
13. Have you smoked at least 100 cigarettes in your entire life?  
 (5 packs = 100 cigarettes) (circle one) 
 No (skip to question 14) Yes 
 
14. Do you NOW smoke cigarettes 1) everyday, 2) some days, or 3) not at all? (circle 
one) 
 1. Every day- On average, about how many cigarettes a day do you smoke? (1 
 pack = 20 cigarettes)   Number of cigarettes ________ 
 
 2. Some days- On average, about how many cigarettes a day do you smoke? (1 
 pack = 20 cigarettes)   Number of cigarettes ________ 
 
 3. Not at all- About how long has it been since you last smoked regularly (that is, 
 daily)? (circle one) 
  i. within the past month (0-1 month ago) 
  ii. within the past 3 months (1-3 months ago) 
  iii. within the 6 months (3-6 months ago) 
  iv. within the past year (6-12 months ago) 
  v.  within the past 5 years (1 to 5 years ago) 
  vi. within the past 15 years (5 to 15 years ago) 
  vii. 15 or more years ago 
  viii. Don’t know/not sure 
  ix.  Never smoked regularly 
 
13. Please circle only one letter that best describes your current activity level: 
 a. I have normal activity without symptoms 
 b. I have some symptoms, but I do not need to spend any extra time resting during 
 the day 
 c. I need some time to rest (e.g. in bed), but it amounts to less than half of my 
 normal daytime  
 d. I need to rest (e.g. in bed) for more than half of my normal daytime. 
 e. I am unable to get out of bed.  
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APPENDIX B: Clinical Factors 
 
Subject # _____     Date of Recruitment: ________ 
MR # ________     Data Collectors Initials: ______ 
 
1. Cancer Diagnosis (circle one) 
 1. Breast    8. Prostate 
 2. Colorectal    9. Bladder 
 3. Lung    10. Endometrial, other gyn cancers ____ 
 4. Lymphoma 
 5. Ovarian 
 6. Cervical 
 7. Testicular 
 
2. Date of initial diagnosis 
_______/_______/_______ 
(month)     (day)      (year)  
 
3. Current TNM Stage: 
Tumor: ______ Nodes: ______ Metastasis: ______ 
 
4. Clinical Stage (circle one) 
 0. Stage 0 
 1. Stage I 
 2. Stage II 
 3. Stage III 
 4. Stage IV 
 5. N/A 
 6. Missing 
 
5. Co-morbidities (circle all that apply) 
 1. Heart Disease   7. Hypertension 
 2. Diabetes    8. Neuromuscular Disease 
 3. Lung    9. Other: ______________________ 
 4. Arthritis    10. None 
 5. Kidney Disease 
 6. Fatigue Syndrome 
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6. Previous treatment(s): (circle one for each subgroup) 
 1. Surgery: 
  1. Yes- Date of most recent surgery:  ______/______/______ 
  2. No     (month)  (day)   (year) 
 
 2. Radiation: 
  1. Definitive RT (circle one) 
   i. Yes – Date: ______/______/______ 
              (month)  (day)    (year) 
     
     # days: ________ 
     
     Total Doses Completed (cGy): ______ 
   ii. No 
 
  2. Hyperfractionated: (circle one) 
   i. Yes 
   ii. No 
   
  3. Palliative RT: (circle one)  
   i. Yes – Date: ______/______/______ 
              (month)  (day)    (year) 
     
     # days: ________ 
     
     Total Doses Completed (cGy): ______ 
   ii. No 
 
 3. Chemotherapy: (circle either yes or no) 
  i. Yes  Date of first treatment: ______/______/______ 
       (month)  (day)   (year) 
    Date of last treatment: ______/______/______ 
       (month)  (day)   (year) 
    Drugs: ________________________________ 
 
  ii. No 
 
4. Bloodwork: (circle one) 
 1. Yes   Hgb: ______ Hct: ______ Date: ______ 
 2. No 
 
5. Has there been any treatment, including surgery, for any health problem, other than 
cancer, in the last month? (circle one) 
 1. Yes   Describe:_____________________________________ 
 2. No 
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APPENDIX C: General Fatigue Scale 
 
Directions: The following items relate to your level of fatigue. Read each statement 
carefully and circle the number that tells you how you feel.   
 
1. My level of fatigue today is: 
  
 1 2 3 4 5 6 7 8 9 10 
No fatigue       Greatest possible fatigue 
____________________________________________________________________ 
 
2. My level of fatigue most days is: 
  
 1 2 3 4 5 6 7 8 9 10 
No fatigue       Greatest possible fatigue 
____________________________________________________________________ 
 
3. In the past 48 hours, the highest level of fatigue I have felt has been: 
  
 1 2 3 4 5 6 7 8 9 10 
No fatigue       Greatest possible fatigue 
____________________________________________________________________ 
 
4. In the past week, the highest level of fatigue I have felt has been: 
  
 1 2 3 4 5 6 7 8 9 10 
No fatigue       Greatest possible fatigue 
____________________________________________________________________ 
 
5. In general, the intensity of my fatigue is: 
  
 1 2 3 4 5 6 7 8 9 10 
No fatigue       Greatest possible fatigue 
____________________________________________________________________ 
 
6. In general, the level of distress I feel due to my fatigue is: 
  
 1 2 3 4 5 6 7 8 9 10 
No distress       Greatest possible distress 
____________________________________________________________________ 
 
7. In general, the amount of impact my fatigue has on my daily activities is: 
  
 1 2 3 4 5 6 7 8 9 10 
No impact       Greatest possible impact 
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APPENDIX D: Brief Pain Inventory 
 
Directions: Check the box that matches your answer. 
 
1. Throughout our lives, most of us have had pain from time to time (such as minor 
headaches, sprains, and toothaches). Have you had pain other than these everyday kinds 
of pain in the past week? 
 
    Yes (Please go to question #2) 
  
    No (You are finished with this part, please skip to next page.) 
 
2. Please rate your pain by circling the one number that best describes your pain in the 
past week.   
 
      No Pain             Pain as bad as 
                 you can imagine 
________________________________________________________________________ 
2. Your pain at its worst in the past week … 1     2     3     4     5     6     7     8     9     10 
 
3. Your pain at its least in the past week …. 1     2     3     4     5     6     7     8     9     10 
 
4. Your pain on the average……….. ……... 1     2     3     4     5     6     7     8     9     10 
 
5. Your pain at right now…………………. 1     2     3     4     5     6     7     8     9     10 
________________________________________________________________________ 
 
 
6. What treatments or medications are you receiving for your pain? 
_______________________________________________________ 
 
 
7. In the past week, how much relief have pain treatments or medications provided? 
Please circle the one percentage that most shows how much. 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
No relief        Complete relief 
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APPENDIX E: Profile of Mood States: Depression Subscale 
 
Directions: The words listed below describe feelings people have.  Read each item 
carefully, then circle the number that indicates HOW YOU HAVE BEEN 
FEELING DURING THE PAST WEEK.  
 
  Not  A     Moderately        Quite a       Extremely 
  at all  little      bit   
 
Sad………… 1  2  3   4  5  
 
Unworthy….. 1  2  3   4  5  
 
Discouraged... 1  2  3   4  5  
 
Lonely……… 1  2  3   4  5  
 
Gloomy…….. 1  2  3   4  5  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
 
APPENDIX F: Pittsburgh Sleep Quality Index 
 
The following questions relate to your usual sleep habits during the past week only. 
Please give the most accurate answer for the majority of days and nights in the past 
week.   
 
Example: During the past week, when have you usually gone to bed at night? 
  
  Usual bed time __10pm__ 
 
Directions: Please fill-in-the-blank in response to questions 1 through 4.   
 
1. During the past week, when have you usually gone to bed at night? 
  
 Usual bed time _______ AM PM 
 
2. During the past week, how long (in minutes) has it usually taken you to fall asleep 
each night? 
  
 Number of minutes ______ 
 
3. During the past week, when have you actually gotten up in the morning? 
  
 Usual getting-up time ______     AM     PM 
 
4. During the past week, how many hours of actual sleep did you get at night?  
(This may be different than the number of hours you spend in bed.)  
 
 Hours of sleep per night ______ 
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Directions: Please circle the number that best matches your answers to questions 5 
through 8.   
 
           Not        Less      Once  3 or 
           At all     Than       or          More 
                  Once/    Twice/     Times/ 
              Week     Week Week  
________________________________________________________________________ 
5. During the past week, how often have you had trouble sleeping because you: 
 
a. Could not get to sleep within 30 minutes…………..    0           1   2        3 
 
b. Woke up in the middle of the night or early morning   0           1   2        3 
 
c. Had to get up to use the bathroom……...…………..    0           1   2        3 
 
d. Could not breathe comfortably……………………..    0           1   2        3 
 
e. Coughed or snored loudly……………...…………..    0           1   2        3 
 
f. Felt too cold…………………………….…………..    0           1   2        3 
 
g. Felt too hot……………………………..…………..    0           1   2        3 
 
h. Had bad dreams………………………...…………..    0           1   2        3 
 
i. Had pain………………………………...…………..    0           1   2        3 
 
j. Other reason(s), please describe:  
___________________________________…………..    0           1   2        3 
___________________________________…………..    0           1   2        3 
___________________________________…………..    0           1   2        3 
 
________________________________________________________________________ 
 
6. During the past week, how often have you taken medication  
(prescribed or “over the counter” to help you sleep …….0           1              2               3 
 
7. During the past week, how often have you have trouble staying awake while  
driving, eating meals, or engaging in social activity……0             1               2               3 
 
________________________________________________________________________ 
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           Very       Fairly     Fairly   Very 
            bad         bad         good      good  
________________________________________________________________________ 
 
8. During the past week, how would you rate your 
sleep quality overall……………………………………0              1               2               3 
________________________________________________________________________ 
 
Directions: Please put a check in the box that corresponds to your answer to question 9. 
 
9. During the past week, how much of a problem has it been for you to keep up enough 
enthusiasm to get things done? 
 
 No problem at all 

 Only a very slight problem 

 Somewhat of a problem

 A very big problem   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
 
Sarah Horsey Simpson 
 
 
CONTACT INFORMATION 
 
1730 N Clark Street, Apt 3701 
Chicago, IL 60614 
Office: (312) 942-2776        Cell: (302) 249-2622        E-mail: shorseysimpson@gmail.com 
 
EDUCATION 
  
Ph.D. Candidate, Clinical Psychology          2010-present 
Drexel University, Philadelphia, PA (APA-accredited)  
 Health Psychology Specialization 
Dissertation title: Sleep Disturbance in Patients with Cancer:  
Testing a Longitudinal Mediation Model of a Symptom Cluster   
 
Clinical Psychology Internship, Health Psychology (APA-accredited)     2012-present 
 Rush University Medical Center in Chicago, IL 
 
M.S. (R), Clinical Psychology             2007-2010 
 Drexel University, Philadelphia, PA (APA-accredited) 
 Thesis title: The Relationship between Insomnia Severity and  
Pre-Sleep Cognitive Arousal: The Moderating Effects of Loneliness 
 
B.S., Psychology (Family Studies Minor)            2001-2005 
James Madison University, Harrisonburg, VA. 
 Graduated Cum Laude with Distinction 
  
INTERESTS & SPECIALTY AREAS 
 
Sleep disorders and behavioral sleep medicine; primary care, medical adherence, psycho-
oncology, obesity and bariatric surgery, health psychology and behavioral medicine 
 
POSITIONS 
 
 
Pre-doctoral Intern, Health Psychology Track        2012-present 
Rush University Medical Center, Department of Behavioral Sciences 
 Behavioral Sleep Medicine rotation 
 Duties: Conduct outpatient evaluations with individuals with sleep disorders. Also 
       provide psychological treatment for the management of sleep disorders.   
Supervisors:  James Wyatt, Ph.D., CBSM 
Jason Ong, Ph.D., CBSM 
Jamie Cvengros, Ph.D. CBSM 
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Psychosocial Oncology rotation 
       Duties: Provide inpatient consultation and treatment and outpatient screening of 
       psychosocial issues for patients with a variety of cancer diagnoses.  
       Supervisors:  Janine Gauthier, Ph.D. 
Veronica Sanchez Varela, Ph.D. 
Geriatric & Rehabilitation Psychology rotation 
Duties: Evaluate psychological and cognitive functioning in an inpatient medical 
rehabilitation setting.  Also recommend and implement tailored psychological 
interventions and participate on an interdisciplinary rehabilitation team.  
       Supervisors:  Erin Emery, Ph.D. 
Jay Behel, Ph.D. 
Judith Stuhr, Ph.D. 
Outpatient Psychotherapy/Behavioral Medicine rotation 
Duties: Evaluate and treat adults presenting to a hospital-affiliated outpatient psychology 
clinic with a variety of psychological and health-related issues.  Also 
       conduct pre-surgical psychological evaluations for bariatric surgery candidates.      
       Supervisors:  Joyce Corsica, Ph.D. 
Megan Hood, Ph.D. 
James Stewart, Ph.D. 
 
Post Bachelorette Fellow (Intramural Research Training Award)        2005-2007       
National Institute of Mental Health, Mood and Anxiety Disorders Program 
 Duties: Coordinator for behavioral and imaging studies investigating facial emotion 
processing and inhibitory reactions in preschool children at genetic risk for bipolar 
disorder, children with ADHD, and adults with bipolar disorder.  Scheduled and managed 
participant visits, administrated paradigms and neuropsychological tests, conducted 
analyses of behavioral and imaging data, designed and managed databases, and prepared 
manuscripts for publication.  
 Supervisors: Ellen Leibenluft, M.D. 
   Daniel Pine, M.D. 
 
CLINICAL TRAINING 
 
Research Interventionist 
Sleep Clinic, Rush University Medical Center            12/2012- study completion 
Duties: Interventionist for clinical trial of adaptive intervention to improve adherence to 
CPAP. 
Supervisor: Jamie Cvengros, Ph.D., CBSM  
 
Pediatric Behavioral Sleep Medicine Extern           2011-2012  
Children’s National Medical Center, Washington, DC 
Duties: Provided outpatient evaluation and treatment of sleep disorders in infants, 
children, and adolescents. Position involved writing reports from diagnostic interviews as 
well as developing and implementing behavior modification plans.  
Supervisors: Daniel Lewin, Ph.D., CBSM 
  Judith Owens, M.D.  
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Psychosocial Counselor                2010-2011 
Abramson Cancer Center, Hospital of the University of Pennsylvania 
Duties: Provided outpatient assessment and psychotherapeutic interventions for patients 
with a variety of cancer diagnoses and their family members. Also maintained open 
communication with patients’ medical team to assist in treatment planning.  
Supervisor: Mark Francis, Ph.D., Clinical Psychologist 
 
Behavioral Sleep Medicine Trainee            2010-2011 
Sleep Center, Philadelphia Veterans Affairs Medical Center 
 Duties: Responsible for intake interviews, developing treatment plans, conducting group 
and individual therapy for insomnia, CPAP compliance, nightmare disorder, and 
circadian rhythm disorders.  Also ordered polysomnography when indicated. Specific 
training in CBT for insomnia and Imagery Rehearsal Training (IRT). 
 Supervisor:  Philip Gehrman, Ph.D. 
 
Research Therapist               2010-2011 
Fox Chase Cancer Center, Psycho-Oncology Program, Cheltenham, PA  
 Duties: Co-led groups for an NIH-funded randomized controlled trial examining the 
efficacy of a group cognitive behavioral intervention compared to group supportive 
therapy for patients with cancer and their significant other in reducing psychological 
distress.  
 Supervisor: Sharon Manne, Ph.D 
 
Behavioral Health Therapist             2009-2010 
Center for Weight and Eating Disorders (CWED), University of Pennsylvania 
Duties: Provided comprehensive psychotherapeutic services to a diverse array of adults 
presenting with obesity and/or disordered eating.  Also conducted psychosocial bariatric 
surgery evaluations. Specific training in CBT for Night Eating Syndrome.   
Supervisor: Kelly Allison, Ph.D.   
 
Assessment Clinician              2008-2009 
Private Practice of Thomas Swirsky-Sacchetti, Ph.D., ABPP, Philadelphia, PA.  
Duties: Provided comprehensive neuropsychological evaluations including designing and 
administering, scoring, case conceptualization, integrated report writing, and participation 
in feedback sessions for children and adults seen for outpatient neuropsychological 
services. Referrals included traumatic brain injury, developmental disorders and learning 
disorders as well as several mental health disability evaluations.  
Supervisior: Thomas Swirsky-Sacchetti, Ph.D. 
 
Group Leader               2004-2005 
Batterers’ Intervention Program, Luray, VA  
Duties: Co-led court mandated group educational sessions; performed analyses on 
program evaluation data collected from clients; acted as liaison between supervisor and 
courts; completed victim contacts and interviews; updated manual for 12 week program 
for individuals found guilty of domestic violence. 
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Supervisor: Judith Weaver, Ed.D.   
 
Intensive Resident Counselor             2003-2004 
Go Getter’s (Psychiatric Rehabilitation Program), Salisbury, MD  
Duties: Provided 24 hour care to residential members suffering from one or more Axis I 
mental disorders in all aspects of daily living skills, including: transportation, meal 
planning and preparation, personal hygiene, medication monitoring, problem solving and 
intervention, and positive role modeling. 
Supervisor: Suzanne Covington, Program Coordinator 
Supervisor: Richard Bearman, Executive Director 
 
Program Assistant             2004 
Counseling and Student Development Center, James Madison University 
Duties: Designed and presented mental health workshops; designed and distribute 
brochure on Alcohol and Substance Abuse; performed alcohol screenings; co-authored 
Counseling and Student Development monthly newsletter; served as committee member 
for Child Abuse Awareness Month and Violence and Sexual Assault Awareness Week. 
Supervisor: Kara Michelle Karr, M.S., Ed.S. 
 
Respite Care Provider                              2003 
Caregivers Community Network, Rockingham County, VA  
 Duties: Provided in-home respite care for families of Alzheimer’s patients.   
Supervisor: Kathleen Pataleo, Program Coordinator  
 
Tutor                2002 
Community Service Block Grant Program (CSBG), Harrisonburg, VA  
 Duties: Provided in-home tutoring for foster and at-risk children. Assisted social workers in 
providing positive social interactions and creating educational structure in home.   
 Supervisor: Joann Grayson, Ph.D., Program Coordinator 
 
RESEARCH ACTIVITIES 
 
Rush University Medical Center, Sleep Disorders Center      2012-present 
Project: Exploring relationships between health-related behaviors and the misalignment 
between diurnal patterns and preferred sleep/wake schedule in patients with insomnia.  
Research activities include conducting a literature review, data analysis, and preparing an 
abstract for submission to national conference. 
 Collaborator: Jason Ong, Ph.D. 
 
Drexel University, Clinical Health Psychology Research Vertical Team       2007-2012 
Activities: Consulted and collaborated with an advisor and a team of fellow graduate 
psychology students with similar research interests. Areas of consultation included 
project development, implementation, as well as activities such as data analysis and 
results presentation.  Team activities focused on individual projects and two group 
projects; 1) utility of an expressive writing paradigm in reducing insomnia severity and 
pre-sleep cognitive arousal in college students with insomnia; and 2) efficacy of a brief 
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psychoeducational intervention targeting maladaptive cognitions known to influence 
college students’ sleep.   
Advisor: Jacqueline Kloss, Ph.D 
 
Master’s Thesis: The Relationship between Insomnia Severity and Pre-Sleep Cognitive 
Arousal: The Moderating Effects of Loneliness. 
Description: Investigated relationships between insomnia severity, cognitive arousal, and 
loneliness in college students. 
Defense Date: April, 2010 
 
Doctoral Dissertation: Sleep Disturbance in Patients with Cancer: Testing a Longitudinal 
Mediation Model of a Symptom Cluster 
Description: Examination of a mediation model as a mechanistic approach to better 
understand how sleep disturbance, pain, depressed mood, and fatigue relate in patients 
with cancer. 
Defense date: October, 2012      
 
Drexel University                       2011 
 Project: Reviewed literature and co-authored multiple published abstracts investigating 
relationships between self-reported sleep quantity/quality and engagement in violence, 
perceived dangerousness of environment, psychological and social functioning, and 
health-related factors in a large urban adolescent sample.     
 Collaborators: Brian Daly, Ph.D., Jacqueline Kloss, Ph.D., Elizabeth Culnan,  
 and Amiee Hildenbrand  
 
Drexel University                2011 
Project: Reviewed literature and co-authored a review article entitled, “The delivery of 
behavioral sleep medicine to college students” published in peer-reviewed Journal of 
Adolescent Health. 
Collaborators: Jacqueline Kloss, Ph.D., Daniel Taylor, Ph.D., and Christina Nash  
 
University of Pennsylvania, Center for Weight and Eating Disorders      2010  
Project: Investigated the role of comorbid binge eating disorder on treatment outcomes in 
patients with night eating syndrome receiving CBT treatment. Research activities 
included conducting literature review, data analyses, preparation and presentation of an 
abstract (poster presentation) at national conference.   
Collaborator: Kelly Allison, Ph.D. 
 
University of Pennsylvania, Center for Weight and Eating Disorders      2010 
Project: Reviewed literature and co-authored an invited submission entitled, “Night 
Eating Syndrome: Overview and Treatment,” to Sports, Cardiovascular, and Wellness 
Nutrition Pulse, a quarterly publication by the Academy of Nutrition and Dietetics. 
Collaborators: Kelly Allision, Ph.D., and Diana Chirinos Medina     
 
St. Christopher’s Hospital for Children, Immunology Department        2007-2008 
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Project: Exploring the role of health beliefs in posttraumatic stress and treatment 
adherence in adolescents with HIV.  Responsible for chart review, conducting follow-up 
appointments, and data entry.   
Supervisors: Beverley Slome Weinberger, Ph.D., and Lamia Barakat, Ph.D. 
 
James Madison University, Student Well-Being Research Team               2003-2005  
 Activities: Consulted and collaborated with a team of faculty members and graduate 
students to design and implement a study investigating academic achievement, well-
being, self efficacy, and life satisfaction in middle school students.  Assisted in literature 
review, study design, submission and IRB approval, collection and management of data, 
interpretation of results, and presentation of the findings with specific intervention 
recommendations to school board. Also hired by graduate psychology department to 
conduct preliminary analyses and analysis of study aims. 
 Honors Thesis: Moving Beyond Predicting Academic Outcomes and Learning Strategies: 
The Impact of Achievement Goals on Middle School Students’ Psychological Well-
Being 
Advisor: Kenneth Barron, Ph.D.    
 
James Madison University, Comparative Psychology Research Team        2003-2004 
 Activities: Assisted in data collection for another student’s dissertation project examining 
stereotypies in deer mice. Also wrote grant for costs associated with upkeep of lab, 
including housing and feeding of animal specimens.       
 Supervisor: Suzanne Baker, Ph.D.  
 
PEER REVIEW PUBLICATIONS 
 
Kloss, J.D., Nash, C. O., Horsey, S. E., & Taylor, D. (2011). The delivery of behavioral sleep 
medicine to college students. Journal of Adolescent Health, 48, 553–561. 
 
Brotman, M. A., Rich, B. A., Guyer, A. E., Lunsford, J. R., Horsey, S. E., Reising, M. M., 
Thomas, L. A., Fromm, S. J., Towbin, K., Pine, D. S., & Leibenluft, E. (2010). Amygdala 
activation during face-emotion processing of neutral faces in children with severe mood 
dysregulation vs. attention deficit hyperactivity disorder vs. bipolar disorder. The American 
Journal of Psychiatry, 16, 61-69.   
 
Brotman, M. A., Guyer, A. E., Lawson, E. S., Horsey, S. E., Rich, B. A., Dickstein, D. P., Pine, 
D. S., & Leibenluft, E. (2008). Facial emotion labeling deficits in children and adolescents at risk 
for bipolar disorder. American Journal of Psychiatry, 165, 385-389. 
 
OTHER PUBLICATIONS 
 
Allison, K. C., Horsey, S. E., & Chirinos, C. M. (2010). Night eating syndrome: Overview and 
treatment. Sports, Cardiovascular, and Wellness Nutrition Pulse, 29, 8-11. 
 
Horsey, S. E., (2004). Alcohol-related sexual assault: Understanding the problem and reducing 
your risk. James Madison University Counseling and Student Development Center Newsletter.     
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MANUSCRIPTS IN PREPARATION 
 
Simpson, S. H., Kloss, J.D., & Barsevick, A. (in preparation). Depressed mood and pain mediate 
the relationship between sleep disturbance and fatigue in patients with cancer undergoing 
chemotherapy.    
 
Simpson, S. H., Kloss, J.D., & Barsevick, A. (in preparation). Confirmatory factor analysis of 
the symptom cluster of pain, depressed mood, sleep disturbance, and fatigue in patients with 
cancer undergoing chemotherapy.    
 
Kloss, J. D., Nash, C., Walsh, C., Culnan, E., Simpson, S. H., Sexton-Radek, K. (submitted). A 
“Sleep 101” program improves knowledge and maladaptive cognitions about sleep among 
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PROFESSIONAL PRESENTATIONS 
 
Simpson, S.H., Kloss, Jacqueline D., & Barsevick, A. A Symptom Cluster Model of Sleep and 
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 Annual Meeting of 
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Horsey, S.E., Culnan, E., Hildenbrand, A.K., Kloss, J.D., & Daly, B.P. (August 2011). 
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Washington, DC.  
 
Hildenbrand, A.K., Horsey, S.E., Culnan, E., Kloss, J.D., & Daly, B.P. (August 2011). Increased 
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Culnan, E., Horsey, S.E., Grandner, M.A. & Kloss, J.D. (June 2011). A Prospective Study of 
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Associated Professional Sleep Societies, LLC, Seattle, WA.  
  
Nash, C.O., Horsey, S., Phillips, C., & Kloss, J.D. (October 2008). A Closer Examination of the 
Insomnia Narratives from the “Clear Your Head Before Bed” Study. Poster presented at the SIG 
meeting at Association for Behavioral and Cognitive Therapies Annual Convention, Orlando, 
FL. 
 
Kloss, J. D., Phillips, C., Wolfman, J., & Horsey, S. E. (June 2008) Preliminary Analyses from 
the Clear Your Head Before Bed Study of College Student Insomniacs.  Poster presented at the 
22
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 Annual Meeting of the Associated Professional Sleep Societies, LLC, Baltimore, MD. 
 
Horsey, S. E., Brotman, M., Rich, B., Blair, R. J., Leibenluft, E (September 2006). Face emotion 
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 Annual 
Scientific Retreat of the Intramural Research Program of the National Institute of Mental Health, 
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Students’ Psychological Well-Being.  Paper presented at the Virginia Psychological Association 
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TEACHING EXPERIENCE 
 
Adjunct Instructor             Spring 2011 
Introduction to Psychology, Drexel University, Psychology Department 
 Independently taught undergraduate classroom section. Responsibilities included 
development and presentation of lecture materials, office hours, scoring homework and 
exams, and assigning grades. Received positive student and department evaluation.   
  
Adjunct Instructor         Summer 2010 
Abnormal Psychology, Drexel University, Psychology Department 
 Independently taught undergraduate classroom section. Responsibilities included 
development and presentation of lecture materials, office hours, scoring homework and 
exams, and assigning grades. Received positive student and department evaluation.   
 
Teaching Assistant                               Fall 2007, Spring 2008 
Abnormal Psychology, Drexel University, Psychology Department 
Responsibilities included lecture development, independent instruction of lab section, 
weekly office hours, and grading papers for this writing intensive course. 
 
Teaching Assistant            Winter 2007 
Pre-Professional Psychology, Drexel University, Psychology Department 
 Responsibilities included guest lectures, assistance in test development, grading papers, 
and weekly office hours for this psychology majors-only course.   
 
 
EDITORIAL ACTIVITIES (co-reviewer) 
 
Journal of Consulting and Clinical Psychology 4 (with Jacqueline Kloss, Ph.D) 
Chronobiology International     1 (with Jacqueline Kloss, Ph.D. 
Journal of Biological Rhythms   1 (with James Wyatt, Ph.D.) 
Behavioral Sleep Medicine    2 (with Jason Ong, Ph.D.) 
Journal of Psychiatric Research   1 (with Jason Ong, Ph.D.) 
 
APA Division 12 Invited Reviewer of Convention Proposals               2011, 2012 
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LEADERSHIP AND SERVICE ACTIVITIES 
 
Poster Judge, 30
th
 Annual Forum for Research and Clinical Investigation Program, Rush 
University Medical Center                        April, 2013 
 Applied for and was selected as judge for student poster submissions to annual university 
research presentation and program. 
 
Sleep Research Society Trainee Symposia Series Subcommittee Member     2012-present 
Applied for and received one year appointment on Sleep Research Society (SRS) Trainee 
Education Advisory Committee (TEAC) subcommittee, responsible for the planning and 
development of the annual SRS trainee educational program at national SLEEP 2013 
conference in Baltimore, MD.  Responsibilities include identifying and selecting 
presentation topics for the scientific program, recruiting speakers for the scientific 
program and career fair, aid in preparation of written program materials, and assist in 
organization and implementation of program day. 
Committee Chair: Philip Gehrman, Ph.D 
Trainee Member-at-Large: Megan Ruiter, Ph.D.        
 
Community Outreach Coordinator, Cancer Committee, Rush University Medical Center    
2012-present 
Applied for and received one year appointment as resident representative for the Rush 
University Medical Center Cancer Committee, which meets quarterly to monitor the 
quality of tumor registry data and analyze trends to improve the patient care experience.  
Responsible for meeting and reporting on CoC Standards 1.8: Monitoring Community 
Outreach and 4.1: Prevention Programs.    
Committee Chair: Michael Liptay, MD   
 
Graduate Assistant, Clinical Psychology Doctoral Program, Drexel University       2009-2010 
 Assisted with various DCT directives, including preparation for APA site visit  
 and annual Ph.D. program interviews. 
 DCT: Evan Forman, Ph.D. 
     
Student Representative, Clinical Psychology Doctoral Program, Drexel University   2008-2009 
Nominated by peers to act as a liaison between graduate students and faculty by 
communicating departmental needs and concerns. Attended faculty meetings and 
maintained student listserv.   
 
Mentor, Psychology Department Mentoring Program, Drexel University        2008-2009 
Mentored an undergraduate psychology student in areas of career development, thesis 
preparation, research training, clinical training, and graduate school preparation and/or 
career choice. 
 
HONORS AND AWARDS 
 
Drexel University Graduate Studies Teaching Award for Outstanding Teaching Assistant, 2008  
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NIH Intramural Research Training Award, NIMH, 2005-2007 
 
Eileen Nelson Award for Senior Excellence in Research, James Madison University, 2005 
 
Best Undergraduate Paper Session Award, Virginia Psychological Association Conference, 2005 
 
Graduate Travel Award (2010) 
Drexel Office of Graduate Studies for travel to ABCT Conference, San Francisco, CA. 
 
Graduate Travel Award (2009) 
Drexel Office of Graduate Studies for travel to SLEEP Conference, Seattle, WA. 
 
Departmental Research Grant (2003)  
Psychology Department, James Madison University 
$500.00  
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Association of Cognitive and Behavioral Therapies (ABCT) 
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American Association of Sleep Medicine (AASM) 
Sleep Research Society (SRS) 
Society of Behavioral Medicine (SBM) 
Society of Behavioral Sleep Medicine (SBSM) 
 
 
 
